US20200390769A1 - Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer - Google Patents
Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer Download PDFInfo
- Publication number
- US20200390769A1 US20200390769A1 US16/914,703 US202016914703A US2020390769A1 US 20200390769 A1 US20200390769 A1 US 20200390769A1 US 202016914703 A US202016914703 A US 202016914703A US 2020390769 A1 US2020390769 A1 US 2020390769A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- milciclib
- sorafenib
- pharmaceutically acceptable
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 title claims abstract description 257
- 229950009655 milciclib Drugs 0.000 title claims abstract description 256
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 155
- 201000011510 cancer Diseases 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title description 36
- 230000001225 therapeutic effect Effects 0.000 title description 19
- 238000009472 formulation Methods 0.000 title description 18
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims abstract description 130
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims abstract description 130
- 229960003787 sorafenib Drugs 0.000 claims abstract description 130
- 238000000034 method Methods 0.000 claims abstract description 126
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 85
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 76
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims abstract description 55
- 229960004836 regorafenib Drugs 0.000 claims abstract description 55
- 229960003784 lenvatinib Drugs 0.000 claims abstract description 53
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims abstract description 53
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims abstract description 53
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 51
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 51
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims abstract description 49
- 229960001796 sunitinib Drugs 0.000 claims abstract description 49
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims abstract description 49
- 229960004390 palbociclib Drugs 0.000 claims abstract description 33
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims abstract description 33
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 31
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 27
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 27
- 208000033781 Thyroid carcinoma Diseases 0.000 claims abstract description 26
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims abstract description 26
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 23
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 22
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 22
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 22
- -1 nivolumab Chemical compound 0.000 claims abstract description 22
- 208000008732 thymoma Diseases 0.000 claims abstract description 22
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 21
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims abstract description 21
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 21
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims abstract description 20
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 20
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 20
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 19
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 19
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 19
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 18
- 229960003301 nivolumab Drugs 0.000 claims abstract description 18
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims abstract description 16
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims description 60
- 201000001441 melanoma Diseases 0.000 claims description 14
- 201000000849 skin cancer Diseases 0.000 claims description 13
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 12
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 11
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 11
- 208000034578 Multiple myelomas Diseases 0.000 claims description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 9
- 230000002123 temporal effect Effects 0.000 claims description 9
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 7
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 7
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 7
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 7
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 7
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 7
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 7
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 7
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 7
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 7
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 7
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 7
- 239000004012 Tofacitinib Substances 0.000 claims description 7
- 229960001686 afatinib Drugs 0.000 claims description 7
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 7
- 229960001611 alectinib Drugs 0.000 claims description 7
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims description 7
- 229960003005 axitinib Drugs 0.000 claims description 7
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 7
- 229960001467 bortezomib Drugs 0.000 claims description 7
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 7
- 229960003736 bosutinib Drugs 0.000 claims description 7
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 7
- 229960001292 cabozantinib Drugs 0.000 claims description 7
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 7
- 229960002438 carfilzomib Drugs 0.000 claims description 7
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 7
- 108010021331 carfilzomib Proteins 0.000 claims description 7
- 229960001602 ceritinib Drugs 0.000 claims description 7
- 229960002271 cobimetinib Drugs 0.000 claims description 7
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 7
- 229960005061 crizotinib Drugs 0.000 claims description 7
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 7
- 229960002465 dabrafenib Drugs 0.000 claims description 7
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 7
- 229960001433 erlotinib Drugs 0.000 claims description 7
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 7
- 229960002584 gefitinib Drugs 0.000 claims description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001507 ibrutinib Drugs 0.000 claims description 7
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 7
- 229960003445 idelalisib Drugs 0.000 claims description 7
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 7
- 229960002411 imatinib Drugs 0.000 claims description 7
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 7
- 229960003648 ixazomib Drugs 0.000 claims description 7
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 7
- 229960004891 lapatinib Drugs 0.000 claims description 7
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 7
- 229960001346 nilotinib Drugs 0.000 claims description 7
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 7
- 229960004378 nintedanib Drugs 0.000 claims description 7
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims description 7
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 7
- 229950011068 niraparib Drugs 0.000 claims description 7
- 229960003278 osimertinib Drugs 0.000 claims description 7
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims description 7
- 229960000639 pazopanib Drugs 0.000 claims description 7
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 7
- 229960003407 pegaptanib Drugs 0.000 claims description 7
- 229960001131 ponatinib Drugs 0.000 claims description 7
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 7
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229950004707 rucaparib Drugs 0.000 claims description 7
- 229960000215 ruxolitinib Drugs 0.000 claims description 7
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 7
- 229960005325 sonidegib Drugs 0.000 claims description 7
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 claims description 7
- 229960001350 tofacitinib Drugs 0.000 claims description 7
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 7
- 229960004066 trametinib Drugs 0.000 claims description 7
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960000241 vandetanib Drugs 0.000 claims description 7
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 7
- 229960003862 vemurafenib Drugs 0.000 claims description 7
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 7
- 208000016676 colorectal gastrointestinal stromal tumor Diseases 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 160
- 239000008194 pharmaceutical composition Substances 0.000 description 55
- 230000002829 reductive effect Effects 0.000 description 53
- 238000003556 assay Methods 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 43
- 239000003814 drug Substances 0.000 description 43
- 239000003981 vehicle Substances 0.000 description 37
- 108091028049 Mir-221 microRNA Proteins 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 239000013543 active substance Substances 0.000 description 25
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- 230000004083 survival effect Effects 0.000 description 22
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 21
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 21
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 20
- 239000002552 dosage form Substances 0.000 description 19
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 19
- 230000001394 metastastic effect Effects 0.000 description 18
- 206010061289 metastatic neoplasm Diseases 0.000 description 18
- 108091061917 miR-221 stem-loop Proteins 0.000 description 17
- 108091063489 miR-221-1 stem-loop Proteins 0.000 description 17
- 108091055391 miR-221-2 stem-loop Proteins 0.000 description 17
- 108091031076 miR-221-3 stem-loop Proteins 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- 239000002775 capsule Substances 0.000 description 15
- 239000003937 drug carrier Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 108091080321 miR-222 stem-loop Proteins 0.000 description 15
- 230000002265 prevention Effects 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000013270 controlled release Methods 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 12
- 230000010534 mechanism of action Effects 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 11
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 11
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 10
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000002356 single layer Substances 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 229940043355 kinase inhibitor Drugs 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 108010058546 Cyclin D1 Proteins 0.000 description 7
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091007914 CDKs Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002679 microRNA Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102100028233 Coronin-1A Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 102100037854 G1/S-specific cyclin-E2 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
- 101000860852 Homo sapiens Coronin-1A Proteins 0.000 description 4
- 101000738575 Homo sapiens G1/S-specific cyclin-E2 Proteins 0.000 description 4
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 4
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 4
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 4
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 4
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 4
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 4
- 230000000340 anti-metabolite Effects 0.000 description 4
- 229940100197 antimetabolite Drugs 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 229960002436 cladribine Drugs 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010004593 Bile duct cancer Diseases 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 230000012746 DNA damage checkpoint Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000009365 Thymic carcinoma Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000004650 oncogenic pathway Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000011506 response to oxidative stress Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- HFPLHASLIOXVGS-UHFFFAOYSA-N 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione Chemical compound S1C(C)=NC(C2=O)=C1C(=O)C=C2NC1=CC=C(C)C=C1 HFPLHASLIOXVGS-UHFFFAOYSA-N 0.000 description 2
- YVXCDLCJCIDFHE-UHFFFAOYSA-N 4-[[6-(ethylamino)-2-[[1-(phenylmethyl)-5-indolyl]amino]-4-pyrimidinyl]amino]-1-cyclohexanol Chemical compound N=1C(NC=2C=C3C=CN(CC=4C=CC=CC=4)C3=CC=2)=NC(NCC)=CC=1NC1CCC(O)CC1 YVXCDLCJCIDFHE-UHFFFAOYSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101150002728 CDC6 gene Proteins 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000004821 Contact adhesive Substances 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 2
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- KAJXOWFGKYKMMZ-UHFFFAOYSA-N LSM-3627 Chemical compound C12=C3C=CC=C[C]3NC2=C2NC3=CC=C[CH]C3=C2C2=C1C(=O)NC2=O KAJXOWFGKYKMMZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100028588 Protein ZNRD2 Human genes 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001740 anti-invasion Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- 229950003462 atiprimod Drugs 0.000 description 2
- SERHTTSLBVGRBY-UHFFFAOYSA-N atiprimod Chemical compound C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 SERHTTSLBVGRBY-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229950009859 dinaciclib Drugs 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006359 hepatoblastoma Diseases 0.000 description 2
- 230000004730 hepatocarcinogenesis Effects 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000046101 human AFP Human genes 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229940124303 multikinase inhibitor Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- UELYDGOOJPRWGF-SRQXXRKNSA-N (2r,3r)-3-[2-[4-(cyclopropylsulfonimidoyl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]oxybutan-2-ol Chemical compound C1=C(C(F)(F)F)C(O[C@H](C)[C@H](O)C)=NC(NC=2C=CC(=CC=2)[S@](=N)(=O)C2CC2)=N1 UELYDGOOJPRWGF-SRQXXRKNSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KFAKESMKRPNZTM-UHFFFAOYSA-N 1,4-dimethoxy-10H-acridine-9-thione Chemical compound N1C2=CC=CC=C2C(=S)C2=C1C(OC)=CC=C2OC KFAKESMKRPNZTM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OOVTUOCTLAERQD-OJMBIDBESA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride Chemical compound Cl.OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O OOVTUOCTLAERQD-OJMBIDBESA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- UELIMKCXGLIYCY-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 UELIMKCXGLIYCY-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-STUHELBRSA-N 4-amino-1-[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-STUHELBRSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- GNCMMKJNEMBGHM-UHFFFAOYSA-N Arcyriaflavin B Natural products C1=CC=C2C3=C(C(=O)NC4=O)C4=C4C5=CC=C(O)C=C5NC4=C3NC2=C1 GNCMMKJNEMBGHM-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- ORXNTNOFHODXCL-UHFFFAOYSA-N CCC(=O)/C1=N/N(C)C2=C1C(C)(C)CC1=CN=C(NC3=CC=C(N4CCN(C)CC4)C=C3)N=C12 Chemical compound CCC(=O)/C1=N/N(C)C2=C1C(C)(C)CC1=CN=C(NC3=CC=C(N4CCN(C)CC4)C=C3)N=C12 ORXNTNOFHODXCL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010060273 Cyclin A2 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001087045 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 101000851526 Homo sapiens Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
- 108091067995 Homo sapiens miR-192 stem-loop Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- UGIOXKVQFJIRMZ-UHFFFAOYSA-N Hygrolidin Natural products C1C(OC(=O)C=CC(O)=O)C(C)C(CC)OC1(O)C(C)C(O)C(C)C1C(OC)C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(C)C(=O)O1 UGIOXKVQFJIRMZ-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027407 Mesothelioma malignant Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100019764 Oryza sativa subsp. japonica TPKA gene Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000004677 childhood cerebellar astrocytic neoplasm Diseases 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229940103380 clolar Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940059359 dacogen Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940070968 depocyt Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- PWUOOJVYZQILBG-UHFFFAOYSA-N fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 102000045726 human PTEN Human genes 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- GEZBIZMDLMTFDB-KJKHOEIASA-N hygrolidin Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(C)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C)[C@H](C)[C@H](OC(=O)\C=C\C(O)=O)C1 GEZBIZMDLMTFDB-KJKHOEIASA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- RBOKLZGCVRXGEP-XTQSDGFTSA-N n-[[5-[(3e)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine Chemical compound CCNCC1=CN=CC(C=2C=C3C(=C/4N=C5C(F)=CC(F)=CC5=N\4)/NNC3=CC=2)=C1C RBOKLZGCVRXGEP-XTQSDGFTSA-N 0.000 description 1
- 229940126426 narazaciclib Drugs 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 229950002433 roniciclib Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000010877 transwell invasion assay Methods 0.000 description 1
- 229940111528 trexall Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000000239 visual pathway Anatomy 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Definitions
- This application relates generally to the treatment of cancers, and more particularly relates to the treatment of cancers with a combination of a cyclin-dependent kinase (CDK) inhibitor and at least one additional anticancer drug.
- CDK cyclin-dependent kinase
- the invention finds utility in the fields of medicine and pharmacotherapy.
- Milciclib which may be referred herein to as Compound 1, or N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, has the following structure:
- Milciclib is a small molecule inhibitor of multiple CDKs, including CDK1, CDK2, CDK4, CDK5, CDK7, and CDK9, and TRKs (TPKA and TRKC), has shown efficacy in several preclinical tumor models (Albanese C et al. (2010) Mol Cancer Ther 9:2243-2254.).
- oral treatment with milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in thymic carcinoma, pancreatic carcinoma and colon cancer (Weiss G J et al. (2013) Invest New Drugs 31:136-144.)
- the major toxicity profile consisted of tremors and gastrointestinal toxicity which was reversible upon treatment suspension. Results from this study recommended a RP2D of 150 mg/day.
- hepatocellular carcinoma is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis.
- a broad range of mechanisms including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response.
- an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential.
- Milciclib exhibiting broad-spectrum inhibitory activities against CDKs, effectively retards proliferation of cancer cells. Therefore, it is reasonable to propose that anticancer activity of milciclib may be potentiated by an inhibitor of tyrosine kinase to produce synergistic anti-tumorigenic activity.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a CDK inhibitor, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- the cancer is non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia,
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the CDK inhibitor is milciclib or a pharmaceutically acceptable salt thereof, and the other anticancer drug is sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, os
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is sorafenib or a pharmaceutically acceptable salt thereof.
- this application pertains to a method wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma, hepatocellular carcinoma, or thyroid carcinoma.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is lenvatinib or a pharmaceutically acceptable salt thereof.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of lenvatinib is 8, 10, 12, 14, 18, 20, 22, 24, 26, 28, 30, 32, or 34 mg once daily.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma or thyroid carcinoma.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is regorafenib or a pharmaceutically acceptable salt thereof.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of regorafenib is 80, 100, or 120 mg once daily for three weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is colorectal cancer or gastrointestinal stromal tumors.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is sunitinib or a pharmaceutically acceptable salt thereof.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of sunitinib is 12.5, 25, 37.5, 50, 62.5, 75, 87.5, or 100 mg once daily continuously or for 4 weeks followed by two weeks of no administration, wherein the cycle is optionally repeated.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma or gastrointestinal stromal tumors.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is nivolumab.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is non-small cell lung cancer or renal cell carcinoma.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is gemcitabine or a pharmaceutically acceptable salt thereof.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of gemcitabine is 1000 mg/m 2 over 30 minutes once weekly for seven weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is breast cancer.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is palbociclib or a pharmaceutically acceptable salt thereof.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of palbociclib is 75, 100, or 125 mg once daily for 3 weeks followed by one week of no administration, wherein the cycle is optionally repeated.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is breast cancer.
- this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered to the patient simultaneously.
- this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in a controlled release form.
- this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are each administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein one or both of the pharmaceutical formulations is in a controlled release form.
- this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered to the patient sequentially.
- this application pertains to any of the methods described herein, wherein administration of milciclib begins before administration of the other anticancer to the patient.
- this application pertains to any of the methods described herein, wherein administration of milciclib begins after administration of the other anticancer to the patient.
- this application pertains to any of the methods described herein, wherein milciclib is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is formulated for oral administration.
- this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in the form of a tablet, pill, or capsule.
- this application pertains to a method of treating or preventing renal cell carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- this application pertains to a method of treating or preventing hepatocellular carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- this application pertains to a method of treating or preventing thyroid carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- this application pertains to any of the methods described herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- this application pertains to any of the methods described herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered to the patient simultaneously.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in a controlled release form.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein one or both of the pharmaceutical formulations is in a controlled release form.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered to the patient sequentially.
- this application pertains to any of the methods described herein, wherein administration of milciclib begins before administration of sorafenib to the patient.
- this application pertains to any of the methods described herein, wherein administration of milciclib begins after administration of sorafenib to the patient.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are each administered in separate pharmaceutical formulations that each further include a pharmaceutically acceptable excipient.
- this application pertains to any of the methods described herein, wherein one or both pharmaceutical formulations are formulated for oral administration.
- this application pertains to any of the methods described herein, wherein each pharmaceutical formulation is independently in the form of a tablet, pill, or capsule.
- this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in temporal proximity.
- this application pertains to any of the methods described herein, wherein the CDK inhibitor and the other anticancer drug are administered in temporal proximity.
- this application pertains to a pharmaceutical composition
- a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug.
- this application pertains to a pharmaceutical composition
- a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- this application pertains to the use of a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- this application pertains to milciclib for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with another anticancer drug.
- this application pertains to sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonideg
- this application pertains to the use of milciclib in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with another anticancer drug.
- this application pertains to use of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, son
- this application pertains to a product comprising milciclib, or a pharmaceutically acceptable salt thereof, and sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatini
- kit comprising:
- a pharmaceutical composition comprising sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonideg
- FIG. 1 is a graph showing the IC50 value of milciclib in MHCC97H cells.
- FIG. 2 is a graph showing the IC50 value of milciclib in MHCC97L cells.
- FIG. 3 is a graph showing the IC50 value of milciclib in HepG2.2.15 cells.
- FIG. 4 is a series of graphs depicting the IC50 of sorafenib, regorafenib, sunitinib, lenvatinib, and palbociclib in a MHCC97H cell proliferation assay.
- FIG. 5 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in MHCC97H cells.
- FIG. 6 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in MHCC97H cells.
- FIG. 7 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in MHCC97H cells.
- FIG. 8 is a set of two graphs showing the IC50 value of palbociclib and the combination of palbociclib and milciclib in MHCC97H cells.
- FIG. 9 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in MHCC97H cells.
- FIG. 10 is a graph showing the IC50 value of sunitinib in MHCC97L cells.
- FIG. 11 is a graph showing the IC50 value of sorafenib in MHCC97L cells.
- FIG. 12 is a graph showing the IC50 value of regorafenib in MHCC97L cells.
- FIG. 13 is a graph showing the IC50 value of lenvatinib in MHCC97L cells.
- FIG. 14 is a graph showing the IC50 value of palbociclib in MHCC97L cells.
- FIG. 15 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in MHCC97L cells.
- FIG. 16 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in MHCC97L cells.
- FIG. 17 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in MHCC97L cells.
- FIG. 18 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in MHCC97L cells.
- FIG. 19 is a set of two graphs showing the IC50 value of palbociclib and the combination of palbociclib and milciclib in MHCC97L cells.
- FIG. 20 is a graph showing the IC50 value of sunitinib in HepG2.2.15 cells.
- FIG. 21 is a graph showing the IC50 value of sorafenib in HepG2.2.15 cells.
- FIG. 22 is a graph showing the IC50 value of regorafenib in HepG2.2.15 cells.
- FIG. 23 is a graph showing the IC50 value of lenvatinib in HepG2.2.15 cells.
- FIG. 24 is a graph showing the IC50 value of palbociclib in HepG2.2.15 cells.
- FIG. 25 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in HepG2.2.15 cells.
- FIG. 26 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in HepG2.2.15 cells.
- FIG. 27 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in HepG2.2.15 cells.
- FIG. 28 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in HepG2.2.15 cells.
- FIG. 29A is a heat map depicting synergism between milciclib and sorafenib in MHCC97H cells. Milciclib concentration is varied on the y-axis and sorafenib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition.
- FIG. 29B is a heat map depicting synergism between milciclib and lenvatinib in MHCC97H cells. Milciclib concentration is varied on the y-axis and lenvatinib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition.
- FIG. 29C is a heat map depicting synergism between milciclib and regorafenib in MHCC97H cells. Milciclib concentration is varied on the y-axis and regorafenib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition.
- FIG. 30 is a graph showing changes in expression of alphafetoprotein (AFP) in MHCC97H cells treated with vehicle of milciclib.
- AFP alphafetoprotein
- FIG. 31 is a series of graphs from the data collected in the Promega Triplex Assay of milciclib in MHCC97H cells.
- FIG. 32 is a series of graphs from the data collected in the Promega Triplex Assay of sorafenib in MHCC97H cells.
- FIG. 33 is a series of graphs from the data collected in the Promega Triplex Assay of regorafenib in MHCC97H cells.
- FIG. 34 is a series of graphs from the data collected in the Promega Triplex Assay of sunitinib in MHCC97H cells.
- FIG. 35 is a series of graphs from the data collected in the Promega Triplex Assay of lenvatinib in MHCC97H cells.
- FIG. 36 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sorafenib in MHCC97H cells.
- FIG. 37 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and regorafenib in MHCC97H cells.
- FIG. 38 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and lenvatinib in MHCC97H cells.
- FIG. 39 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sunitinib in MHCC97H cells.
- FIG. 40 is a series of graphs from the data collected in the Promega Triplex Assay of milciclib in MHCC97L cells.
- FIG. 41 is a series of graphs from the data collected in the Promega Triplex Assay of regorafenib in MHCC97L cells.
- FIG. 42 is a series of graphs from the data collected in the Promega Triplex Assay of sunitinib in MHCC97L cells.
- FIG. 43 is a series of graphs from the data collected in the Promega Triplex Assay of sorafenib in MHCC97L cells.
- FIG. 44 is a series of graphs from the data collected in the Promega Triplex Assay of lenvatinib in MHCC97L cells.
- FIG. 45 is a series of graphs from the data collected in the Promega Triplex Assay of palbociclib in MHCC97L cells.
- FIG. 46 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sorafenib in MHCC97L cells.
- FIG. 47 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and regorafenib in MHCC97L cells.
- FIG. 48 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sunitinib in MHCC97L cells.
- FIG. 49 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and lenvatinib in MHCC97L cells.
- FIG. 50 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and palbociclib in MHCC97L cells.
- FIG. 51 is a series of photographs depicting the results of a wound-healing assay with milciclib in MHCC97H cells.
- FIG. 52 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in MHCC97H cells.
- FIG. 53 is a series of photographs depicting the results of a wound-healing assay with sunitinib and the combination of sunitinib and milciclib in MHCC97H cells.
- FIG. 54 is a series of photographs depicting the results of a wound-healing assay with lenvatinib and the combination of lenvatinib and milciclib in MHCC97H cells.
- FIG. 55 shows is a series of photographs depicting the results of a wound-healing assay with regorafenib and the combination of regorafenib and milciclib in MHCC97H cells.
- FIG. 56 is a series of photographs depicting the results of a wound-healing assay with milciclib in MHCC97L cells.
- FIG. 57 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in MHCC97L cells.
- FIG. 58 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of regorafenib and milciclib in MHCC97L cells.
- FIG. 59 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sunitinib and milciclib in MHCC97L cells.
- FIG. 60 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of lenvatinib and milciclib in MHCC97L cells.
- FIG. 61 is a series of photographs depicting the results of a wound-healing assay with milciclib in HepG2.2.15 cells.
- FIG. 62 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in HepG2.2.15 cells.
- FIG. 63 is a series of photographs depicting the results of a wound-healing assay with regorafenib and the combination of regorafenib and milciclib in HepG2.2.15 cells.
- FIG. 64 is series of bar graphs displaying the results of an EMT assay with milciclib (A), regorafenib (B), sorafenib (C), sunitinib (D), and lenvatinib (E) in MHCC97L cells.
- FIG. 65 is series of bar graphs displaying the results of an EMT assay with milciclib (A), regorafenib (B), sorafenib (C), sunitinib (D), and lenvatinib (E) in MHCC97H cells.
- FIG. 66 is a schematic depicting the experimental design of in vivo studies wherein athymic mice with livers injected with MHCC97H cells were treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIG. 67 is a graph showing weight of mice livers following treatment via oral administration with sorafenib, milciclib, sorafenib+milciclib.
- FIG. 68 is a graph showing weight of mice liver tumors following treatment via oral administration with sorafenib, milciclib, sorafenib+milciclib.
- FIG. 69 is a series of photographs depicting changes in MHCC97H orthotopic HCC mouse liver tumor burden following treatment with vehicle, milciclib, sorafenib, or milciclib+sorafenib.
- FIG. 70 is a graph depicting changes in AFP serum levels in athymic mice with livers injected with MHCC97H cells were treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIGS. 71A and 71B are a series of graphs depicting relative expression of miR-221 ( 71 A) and miR-222 ( 71 B) miRNAs in athymic mice with livers injected with MHCC97H cells treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIG. 72 is a series of graphs depicting relative expression of p27 kip1 (A), p21 (B), p57 (C), and p53 (D) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIGS. 73A and 73B are a series of graphs depicting relative expression of Cyclin D1 ( 73 A) and Cyclin E2 ( 73 B) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIGS. 74A, 74B, and 74C are a series of graphs depicting relative expression of MKI67 ( 74 A), c-Myc ( 74 B) and Cdc6 ( 74 C) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib.
- FIG. 75 is a series of western blots depicting changes in expression of pAKT Ser473 , AKT, Cyclin D1, c-Myc, and PTEN in cells cultured from orthotopic HCC model mice following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib. Actin is used as a loading control.
- FIG. 76 is a schematic depicting milciclib mechanism of action in hepatocellular carcinoma.
- a CDK inhibitor refers not only to a single inhibitor but also to a combination of two or more different inhibitors
- a dosage form refers to a combination of dosage forms as well as to a single dosage form, and the like.
- the term “patient” or “individual” or “subject” refers to any person or mammalian subject for whom or which therapy is desired, and generally refers to the recipient of the therapy to be practiced according to the invention.
- CDK inhibitor refers to a compound that inhibits the enzyme in humans referred to as cyclin-dependent kinase. Examples include, without limitation, milciclib, palbociclib, dinaciclib, P276-00, roniciclib, ribociclib, P1446A-05, AT7519M, SNS-032, SCH 727965, AG-024322, hygrolidin, fascaplysin, abemaciclib, arcyriaflavin A, CINK4, AM-5992, CDK4 Inhibitor (CAS #546102-60-7), CDK4 Inhibitor III (CAS #265312-55-8), Cdk4/6 Inhibitor IV (CAS #359886-84-3), MM-D37K, NSC 625987, ON-123300, or any pharmaceutically acceptable salt thereof.
- the CDK inhibitor is milciclib.
- anticancer drug or “anticancer agent” includes kinase inhibitor drugs which refers to any member of the group of anticancer drugs that specifically targets protein kinases that are altered in cancer cells and account for some of their abnormal growth.
- the anticancer drug is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, to
- the anticancer drug is sorafenib. In one embodiment, the anticancer drug is lenvatinib. In one embodiment, the anticancer drug is regorafenib. In one embodiment, the anticancer drug is sunitinib. In one embodiment, the anticancer drug is palbociclib.
- anticancer drugs include, without limitation, an alkylating agent, an antibiotic, an anti-metabolite, a detoxifying agent, an interferon, a polyclonal or monoclonal antibody, an EGFR inhibitor, a HER2 inhibitor, a histone deacetylase inhibitor, a hormone; a mitotic inhibitor, an MTOR inhibitor, a multi-kinase inhibitor, a serine/threonine kinase inhibitor, a tyrosine kinase inhibitors, a VEGF/VEGFR inhibitor, a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), a cytidine analogue drug, or any chemotherapeutic, anti-neoplastic or anti-proliferative agent listed in www.cancer
- active agent When referring to an active agent, applicant intends the term “active agent” to encompass not only the specified molecular entity but also its pharmaceutically acceptable, pharmacologically active analogs, including, but not limited to, salts, esters, amides, prodrugs, conjugates, active metabolites, crystalline forms (including polymorphs), enantiomers, and other such derivatives, analogs, and related compounds.
- treating and “treatment” include the following actions: (i) preventing a particular disease or disorder from occurring in a subject who may be predisposed to the disease or disorder but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease by reducing or eliminating symptoms and/or by causing regression of the disease.
- unit dosage forms refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients.
- two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of milciclib, such that the unit dosage in each tablet or capsule is approximately 50% of the therapeutically effective amount.
- an effective amount and “therapeutically effective amount” of a compound is meant a nontoxic but sufficient amount of an active agent to provide the desired effect, i.e., treatment of cancer.
- a “subject in need thereof” is a subject having cancer, or a subject having an increased risk of developing cancer relative to the population at large.
- cancer includes solid tumors, as well as, hematologic tumors and/or malignancies.
- a “cancer cell” or “cancerous cell” is a cell manifesting a cell proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells. Cancer cells can be identified by histological typing or grading of a tissue sample (e.g., a biopsy sample). Cancer cells can be identified through the use of appropriate molecular markers.
- Exemplary cancers include, but are not limited to, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodeimal tumors, visual pathway and hypothalamic glioma, breast cancer, triple negative breast cancer, bronchial
- the present application provides methods of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers or excipients, in combination with a therapeutically effective amount of a second agent, i.e., an anticancer drug, with one or more pharmaceutically acceptable carriers or excipients, wherein the cancer is treated.
- a second agent i.e., an anticancer drug
- the anticancer drug is any compound disclosed herein other than milciclib.
- the cancer can be a hematologic tumor or malignancy, or a solid tumor (or tumors), or a refractory solid tumor.
- the cancer is selected from the group consisting of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer (e.g., triple negative breast cancer), prostate cancer, pancreatic cancer, or thymoma (i.e., thymic carcinoma).
- This method of treating cancer includes a reduction in tumor size.
- the cancer is metastatic cancer and this method of treatment includes inhibition of metastatic cancer cell invasion.
- the other anticancer drug or agent can be an alkylating agent; an antibiotic; an anti-metabolite; a detoxifying agent; an interferon; a polyclonal or monoclonal antibody; an EGFR inhibitor; a HER2 inhibitor; a histone deacetylase inhibitor; a hormone; a mitotic inhibitor; an MTOR inhibitor; a multi-kinase inhibitor; a serine/threonine kinase inhibitor; a tyrosine kinase inhibitors; a VEGF/VEGFR inhibitor; a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), a cytidine analogue drug or any chemotherapeutic, anti-neoplastic or anti-proliferative agent listed in www.cancer.
- the other anticancer agent is an anti-metabolite or a nucleoside analog.
- exemplary anti-metabolites or nucleoside analogs include, but are not limited to, fluorouracil (Adrucil); capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purinethol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus); clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); cytarabine liposomal (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrex
- the other anticancer drug or agent is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- compositions suitable for administration typically comprise the compound (i.e. including the active compound), and a pharmaceutically acceptable excipient or carrier.
- pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin.
- Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like.
- the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like.
- Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this application.
- Liposomes and non-aqueous vehicles such as fixed oils may also be used.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- milciclib, or a pharmaceutically acceptable salt thereof, and/or the other anticancer drug is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, etc.) of milciclib, or a pharmaceutically acceptable salt thereof (as an active ingredient) and/or the other anticancer drug or agent, with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the application). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation.
- a therapeutically effective amount e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, etc.
- standard pharmaceutical carriers or diluents i.e., by producing a pharmaceutical composition of the application.
- treating describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes decreasing or alleviating the symptoms or complications, or eliminating the disease, condition or disorder.
- preventing describes stopping the onset of the symptoms or complications of the disease, condition or disorder.
- treating cancer results in a reduction in size of a tumor.
- a reduction in size of a tumor may also be referred to as “tumor regression.”
- tumor size is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater.
- Size of a tumor may be measured by any reproducible means of measurement. In a preferred aspect, size of a tumor may be measured as a diameter of the tumor.
- treating cancer results in a reduction in tumor volume.
- tumor volume is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater.
- Tumor volume may be measured by any reproducible means of measurement.
- treating cancer results in a decrease in number of tumors.
- tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%.
- Number of tumors may be measured by any reproducible means of measurement.
- number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification.
- the specified magnification is 2 ⁇ , 3 ⁇ , 4 ⁇ , 5 ⁇ , 10 ⁇ , or 50 ⁇ .
- treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site.
- the number of metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%.
- the number of metastatic lesions may be measured by any reproducible means of measurement.
- the number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification.
- the specified magnification is 2 ⁇ , 3 ⁇ , 4 ⁇ , 5 ⁇ , 10 ⁇ , or 50 ⁇ .
- treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone.
- the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects.
- the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- treating cancer results in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not milciclib, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
- the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days.
- An increase in average survival time of a population may be measured by any reproducible means.
- an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound.
- an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone.
- treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population.
- treating cancer results a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not milciclib, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
- the mortality rate is decreased by more than 2%; more preferably, by more than 5%; more preferably, by more than 10%; and most preferably, by more than 25%.
- a decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means.
- a decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound.
- a decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.
- treating cancer results in a decrease in tumor growth rate.
- tumor growth rate is reduced by at least 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%.
- Tumor growth rate may be measured by any reproducible means of measurement. In a preferred aspect, tumor growth rate is measured according to a change in tumor diameter per unit time.
- treating cancer results in a decrease in tumor regrowth.
- tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%.
- Tumor regrowth may be measured by any reproducible means of measurement.
- tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment.
- a decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.
- controlled release or “controlled release form” refers to a drug-containing formulation or fraction thereof in which release of the drug is not immediate, i.e., with a “controlled release” formulation, administration does not result in immediate release of the drug into an absorption pool.
- controlled release as used herein includes sustained release and delayed release formulations.
- sustained release (synonymous with “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period.
- delayed release is also used in its conventional sense, to refer to a drug formulation which, following administration to a patient, provides a measurable time delay before drug is released from the formulation into the patient's body.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
- pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
- “Pharmacologically active” or simply “active” as in a “pharmacologically active” derivative or analog, refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
- Administration of the active agents may be carried out using any appropriate mode of administration.
- administration can be, for example oral or parenteral, although oral administration is preferred.
- the pharmaceutical formulation may be a solid, semi-solid or liquid, such as, for example, a tablet, a capsule, a caplet, a liquid, a suspension, an emulsion, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage.
- suitable pharmaceutical formulations and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, Pa.: Mack Publishing Co., 1995).
- oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated.
- Preferred oral dosage forms are capsules and tablets.
- unit dosage forms refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients.
- two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of each active agent, such that the unit dosage in each tablet or capsule is approximately 50% of the therapeutically effective amount.
- Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred.
- tablets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, and the like.
- Capsules are also preferred oral dosage forms, in which case the active agent-containing composition may be encapsulated in the form of a liquid or solid (the latter including particulates such as granules, beads, powders or pellets).
- Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred.
- Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited earlier herein, which describes materials and methods for preparing encapsulated pharmaceuticals.
- sustained release dosage forms are formulated by dispersing the active agents within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug-containing dosage form with such a material.
- Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g.
- Sustained release dosage forms herein may be composed of the acrylate and methacrylate copolymers available under the tradename “Eudragit” from Rohm Pharma (Germany).
- the Eudragit series E, L, S, RL, RS, and NE copolymers are available as solubilized in organic solvent, in an aqueous dispersion, or as a dry powder.
- Preferred acrylate polymers are copolymers of methacrylic acid and methyl methacrylate, such as the Eudragit L and Eudragit S series polymers.
- any of the pharmaceutical formulations may be formulated for sustained release, i.e., in a sustained release dosage form.
- Preparations according to this invention for parenteral administration include sterile aqueous and non-aqueous solutions, suspensions, and emulsions.
- Injectable aqueous solutions contain the active agent in water-soluble form.
- non-aqueous solvents or vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like.
- Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsifiers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran.
- Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium.
- the active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection.
- Each of the active agents may in addition be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent or agents are contained within a laminated structure that serves as a drug delivery device to be affixed to the skin.
- the drug composition is contained in a layer, or “reservoir,” underlying an upper backing layer.
- the laminated structure may contain a single reservoir, or it may contain multiple reservoirs.
- the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery.
- the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.
- Transdermal drug delivery systems may in addition contain a skin permeation enhancer.
- the active agents may be formulated in a depot preparation for controlled release of the active agents, preferably sustained release over an extended time period.
- sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection).
- a “daily dose” of a particular material refers the amount of the material administered in a day.
- a daily dose can be administered as a single dose or as multiple doses. When a daily dose is administered as multiple doses, the daily dose is the sum of the amount of material administered in all of the multiple doses that are administered over the course of one day. For example, a daily dose of 12 mg can be administered in a single 12 mg dose once per day, in 6 mg doses administered twice per day, in 4 mg doses administered three times per day, in 2 mg doses administered six times per day, etc.
- the multiple doses can be the same or different doses of the material, unless otherwise specified.
- a daily dose of 12 mg can include, for example, a 10 mg intramuscular dose and a 2 mg oral dose administered over the course of one day.
- Administration of one compound “with” a second compound includes but is not limited to cases where the two compounds are administered simultaneously or substantially simultaneously.
- administration of a first compound with a second compound can include administering the first compound in the morning and administering the second compound in the evening, as well as administering the first and second compounds in the same dosage form or in two different dosage forms that at the same or nearly the same time.
- milciclib will generally reduce the quantity of the second drug or agent needed to achieve a therapeutic effect when administered as a monotherapy, and, conversely, the other anticancer drug or agent will generally reduce the quantity of milciclib required.
- the active agents may be administered separately, at the same or at different times of day, or they be administered in a single pharmaceutical formulation.
- “temporal proximity” means that administration of the other anticancer drug occurs within a time period before or after the administration of the CDK inhibitor (e.g., milciclib), such that the therapeutic effect of the other kinase inhibitor drug overlaps with the therapeutic effect of the CDK inhibitor (e.g., milciclib). In some embodiments, the therapeutic effect of the other kinase inhibitor drug completely overlaps with the therapeutic effect of the CDK inhibitor (e.g., milciclib).
- “temporal proximity” means that administration of the other kinase inhibitor drug occurs within a time period before or after the administration of the CDK inhibitor (e.g., milciclib), such that there is a synergistic effect between the other kinase inhibitor drug and the CDK inhibitor.
- the CDK inhibitor e.g., milciclib
- Temporal proximity may vary according to various factors, including but not limited to, the age, gender, weight, genetic background, medical condition, disease history, and treatment history of the subject to which the therapeutic agents are to be administered; the disease or condition to be treated or ameliorated; the therapeutic outcome to be achieved; the dosage, dosing frequency, and dosing duration of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the route(s) through which the therapeutic agents are administered.
- “temporal proximity” means within 15 minutes, within 30 minutes, within an hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within a week, within 2 weeks, within 3 weeks, within 4 weeks, with 6 weeks, or within 8 weeks.
- multiple administration of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent.
- temporal proximity may change during a treatment cycle or within a dosing regimen.
- IC50 values by cell proliferation assay were determined for MHCC97H and MHCC97L (highly metastatic hepatocellular carcinoma cell line, derived from humans) and HepG2.2.15 cells (derived from the human hepatoblastoma cell line HepG2).
- the cells were treated with milciclib, sorafenib, regorafenib, sunitinib, and lenvatinib, individually or in combination.
- Each inhibitor exhibited a dose dependent decrease in cell proliferation with comparable half maximal inhibitory concentration (IC50) across the three cell lines: ( FIGS. 1 and 4 —MHCC97H cells; FIGS. 2 and 10-14 —MHCC97L cells; and FIGS. 3 and 20-24 , HepG2.2.15 cells.)
- MHCC97L and MHCC97H cells Increasing concentration of inhibitors with a fixed concentration of milciclib was tested on MHCC97L and MHCC97H cells to determine the synergistic effect on inhibition of cell proliferation.
- the individual IC 50 was 12 ⁇ M but with the combination with milciclib the IC 50 was 6.7 ⁇ M in MHCC97H ( FIG. 29A ).
- the individual IC 50 was 0.28 ⁇ M but with the combination with milciclib the IC 50 was 0.12 ⁇ M in MHCC97H ( FIG. 29B ).
- the individual IC 50 was 4.7 ⁇ M but with the combination with milciclib the IC 50 was 1.9 ⁇ M in MHCC97H ( FIG. 29C ).
- MHCC97H cells were shown to produce human Alphafetoprotein (AFP)
- Promega ApoTox-GloTM Triplex assays were also performed. Milciclib in combination with other TKIs at various concentrations decreased the cell viability and increased caspase 3/7 activity in MHCC97H cells ( FIGS. 31-39 ) and MHCC97L cells ( FIGS. 40-50 ) in a dose-dependent manner compared to those in vehicle-treated cells.
- EMT Epidermal to Mesenchymal Transition
- Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P ⁇ 0.005) ( FIG. 64 ).
- the inclusion of milciclib or TKIs alone resulted in statistically significant inhibition (P ⁇ 0.05) in cell migration in MHCC97H cells.
- Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P ⁇ 0.005), demonstrative of the anti-invasive potential of milciclib ( FIG. 65 ).
- milciclib acts via specifically downregulating miR221/222. Gene expression studies suggest that milciclib possibly exerts its action through downregulation of miR-221 and miR-222. Data suggest that oral treatment with milciclib exerts its activity via downregulation of miR-221 and miR-222 ( FIGS. 71A and 71B ). These data suggest that milciclib specifically acts via reducing expression of miR-221 and miR-222, which are known to be major culprits of hepatocarcinogenesis.
- the mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib as it upregulated the expression of tumor suppressors such as p27, p21, p53 and p57 ( FIGS. 72A , B, C, D).
- Oral administration of milciclib alone or in combination with sorafenib downregulated expression of cell proliferation genes such as MKI67, cdc6, c-Myc FIGS. 74A, 74B, 74C ).
- the mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib.
- Mechanistic studies revealed a reduction in pAKT, c-Myc and cyclin D1 expression and upregulation of PTEN in liver samples derived from milciclib and milciclib and sorafenib administered animals as compared to vehicle treated group ( FIG. 75 ).
- Data from cell culture studies and from orthotopic HCC model in nude mice suggest that oral treatment with milciclib exerts its activity via a new mechanism.
- HCC Hepatocellular Carcinoma
- Hepatocellular carcinoma is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis.
- a broad range of mechanisms including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response. Consequently, HCC is typically associated with overexpression of receptor tyrosine kinases (RTK) and excessive oxidative stress (ROS).
- RTK receptor tyrosine kinases
- ROS excessive oxidative stress
- HCC is also associated with overexpression of miR-221, miR-222 and CDKs, resulting in dysregulation of cell cycle, which leads to excessive proliferation of hepatocytes.
- Treatment with milciclib is known to inhibit miR-221/miR-222 and a number of CDKs and it can effectively reduce proliferation of hepatocytes. Therefore, collectively combination of milciclib with an inhibitor of RTK may produce synergistic effect in reducing expression of c-myc and in total tumor growth and progression.
- an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential.
- a pharmaceutical composition of the application is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- a compound or pharmaceutical composition of the application can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
- a compound of the application may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
- the dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects.
- the state of the disease condition and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
- therapeutically effective amount refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
- the effect can be detected by any assay method known in the art.
- the precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
- Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
- the disease or condition to be treated is cancer.
- the disease or condition to be treated is a cell proliferative disorder.
- the therapeutically effective amount of milciclib is 1-500 mg administered one or more times over a day for up to 30 or more days, followed by 1 or more days of non-administration of milciclib.
- This type of treatment schedule i.e., administration of milciclib on consecutive days followed by non-administration of milciclib on consecutive days may be referred to as a treatment cycle.
- a treatment cycle may be repeated as many times as necessary to achieve the intended affect.
- the therapeutically effective amount of milciclib is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470
- the therapeutically effective amount of milciclib is 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg once or twice daily for one, two, three, four, five, six, seven, eight, nine, or ten consecutive days, followed by non-administration for one, two, three, four, five, six, or seven consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- the therapeutically effective amount of milciclib is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 mg once or twice daily for one, two, three, four, five, six, or seven consecutive days, followed by non-administration for one, two, three, four, five, six, or seven consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- the therapeutically effective amount of milciclib is 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, or 125 mg once daily for four consecutive days, followed by non-administration for three consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs.
- the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
- Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
- Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
- Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect.
- Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
- Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
- compositions containing active compounds of the present application may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
- Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the active compounds are prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the application are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
- the dosages of the pharmaceutical compositions used in accordance with the application vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage.
- the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer.
- Dosages can range from about 0.01 mg/kg per day to about 3000 mg/kg per day. In preferred aspects, dosages can range from about 1 mg/kg per day to about 1000 mg/kg per day.
- the dose will be in the range of about 0.1 mg/day to about 50 g/day; about 0.1 mg/day to about 25 g/day; about 0.1 mg/day to about 10 g/day; about 0.1 mg to about 3 g/day; or about 0.1 mg to about 1 g/day, in single, divided, or continuous doses (which dose may be adjusted for the patient's weight in kg, body surface area in m2, and age in years).
- An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped.
- the term “dosage effective manner” refers to amount of an active compound to produce the desired biological effect in a subject or cell.
- compositions can include co-formulations of milciclib and any of the compounds described herein.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- the present application also relates to the following:
- a method of treating or preventing cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib, or a pharmaceutically acceptable salt thereof.
- a method of treating or preventing non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- the other anticancer drug is sorafenib or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- the cancer is renal cell carcinoma, hepatocellular carcinoma, or thyroid carcinoma.
- the other anticancer drug is lenvatinib or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of lenvatinib is 8, 10, 12, 14, 18, 20, 22, 24, 26, 28, 30, 32, or 34 mg once daily.
- the cancer is renal cell carcinoma or thyroid carcinoma.
- the other anticancer drug is regorafenib or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of regorafenib is 80, 100, or 120 mg once daily for three weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- the cancer is colorectal cancer or gastrointestinal stromal tumors.
- the other anticancer drug is sunitinib or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of sunitinib is 12.5, 25, 37.5, 50, 62.5, 75, 87.5, or 100 mg once daily continuously or for 4 weeks followed by two weeks of no administration, wherein the cycle is optionally repeated.
- the cancer is renal cell carcinoma or gastrointestinal stromal tumors.
- the cancer is non-small cell lung cancer or renal cell carcinoma.
- the other anticancer drug is palbociclib or a pharmaceutically acceptable salt thereof.
- the therapeutically effective amount of palbociclib is 75, 100, or 125 mg once daily for 3 weeks followed by one week of no administration, wherein the cycle is optionally repeated.
- the cancer is breast cancer.
- the other anticancer drug is gemcitabine.
- the therapeutically effective amount of gemcitabine is 1000 mg/m 2 over 30 minutes once weekly for seven weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- the cancer is breast cancer.
- the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is repeated as multiple times, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more times.
- the therapeutically effective amount of milciclib is about 100 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- the therapeutically effective amount of milciclib is 100 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- M. Milciclib and the other anticancer drug are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- the pharmaceutical formulation is in a controlled release form.
- N. Milciclib and the other anticancer drug are each administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient.
- each formulation further includes a pharmaceutically acceptable excipient.
- one or both of the pharmaceutical formulations is in a controlled release form.
- milciclib and the other anticancer drug are administered to the patient sequentially.
- the administration of milciclib begins before administration of the other anticancer drug to the patient.
- the administration of milciclib begins after administration of the other anticancer drug to the patient.
- P. Milciclib is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- the other anticancer drug is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- any of the pharmaceutical formulations are formulated for oral administration.
- the pharmaceutical formulation is in the form of a tablet, pill, or capsule.
- T Any of methods disclosed herein, wherein the method of treating or preventing hepatocellular carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib.
- V Any of methods disclosed herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- a method of treating or preventing thyroid carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib.
- sorafenib any of methods disclosed herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- AA Any of methods disclosed herein, wherein milciclib and sorafenib are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- CC CC. Any of methods disclosed herein, wherein milciclib and sorafenib are administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient. In one embodiment, one or both of the pharmaceutical formulations is in a controlled release form.
- DD Any of methods disclosed herein, wherein milciclib and sorafenib are administered to the patient sequentially.
- GG Any of methods disclosed herein, wherein milciclib and sorafenib are each administered in separate pharmaceutical formulations that each further include a pharmaceutically acceptable excipient.
- one or both pharmaceutical formulations are formulated for oral administration.
- each pharmaceutical formulation is independently in the form of a tablet, pill, or capsule.
- HH. Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of cancer in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug.
- JJ. Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- KK. Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of cancer in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- LL. Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug.
- MM. Milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- MHCC97H and MHCC97L highly metastatic hepatocellular carcinoma cell line, derived from humans
- HepG2.2.15 cells are derived from the human hepatoblastoma cell line HepG2.
- Cells (MHCC97H, MHCC97L, and HepG2.2.15) were cultured for 24 hours in 2% FBS and then were trypsinized, resuspended in 2% FBS and seeded in a rat collagen coated 96-well plate at a density of 10,000 cells/100 ⁇ l/well, a day before the experiment and cultured at 37° C. in 5% CO 2 .
- the cells were treated the next day with milciclib, sorafenib, regorafenib, sunitinib, and lenvatinib, individually or in combination in DMEM/F12+2% FBS+for 72 hours prior to the addition of WST-1 reagent. About 100 ⁇ L media was added to control well.
- FIGS. 1 and 4 MHCC97H cells
- FIGS. 2 and 10-14 MHCC97L cells
- FIGS. 3 and 20-24 HepG2.2.15 cells.
- Lenvatinib exhibited the lowest IC 50 value followed by milciclib, regorafenib, sorafenib and sunitinib.
- the arrow represents the mid-point of combination of TKIs with milciclib.
- the individual IC 50 was 12 ⁇ M but with the combination with milciclib the IC 50 was 6.7 ⁇ M in MHCC97H ( FIG. 29A ).
- the individual IC 50 was 0.28 ⁇ M but with the combination with milciclib the IC 50 was 0.12 ⁇ M in MHCC97H ( FIG. 29B ).
- the individual IC 50 was 4.7 ⁇ M but with the combination with milciclib the IC 50 was 1.9 ⁇ M in MHCC97H ( FIG. 29C ).
- MHCC97H cells were seeded at a density of 500,000 cells/2 mL/well on a 6 well culture plate and incubated overnight at 37° C. in a humidified CO 2 incubator. Cells were then treated with 1.3 ⁇ M milciclib or vehicle in DMEM/F12+2% FBS for 72 hours. Subsequently, cells were lysed in RIPA buffer, the supernatant was collected and used to perform ELISA assay as per the manufacturer's instructions. In orthotopic HCC mouse model, levels of serum marker alpha-fetoprotein (AFP) were determined on day 0, 6, 12, 18, 24, 30, 36, 42 and 48 using High Range AFP kit as per manufacturer's instructions.
- AFP serum marker alpha-fetoprotein
- MHCC97H cells Freshly cultured MHCC97H cells were treated with 1.3 ⁇ M milciclib for 72 hours to determine the AFP levels. Appreciably lower levels of AFP were detected in milciclib treated cells as compared to vehicle control ( FIG. 30 ).
- the HCC cells were seeded at a density of 10,000 cells/100 ⁇ L in each well of a rat collagen coated 96 well plate and allowed to grow overnight in 5% CO 2 at 37° C. The cells were then treated with different concentrations of each agent alone or in combination with 1.3 milciclib in MHCC97H and 1.16 ⁇ M milciclib in MHCC97L cells for 48 hours. Promega ApoTox-Glo Triplex assay (Madison, Wis.) was used according to manufacturer's instructions to determine the number of viable cells, cell death because of apoptosis and cytotoxic effect on cells.
- the viability/cytotoxicity reagent containing both the GF-AFC substrate and the bis-AAF-R110 substrate, was added to all wells and incubated for 30 minutes and was measured at an optical density of 400EX/505EM for viability and 485EX/520EM for cytotoxicity.
- caspase-glo 3/7 was added to all wells, mixed briefly at 500 rpm for 30 seconds, then incubated at room temperature for 30 minutes and luminescence was measured which is proportional to the amount of caspase activity present. See Ito H, Uchida T, Makita K. Ketamine causes mitochondrial dysfunction in human induced pluripotent stem cell-derived neurons. PLoS One. 2015; 10: e0128445) for experimental details. Reference is incorporated herein in its entirety.
- Milciclib in combination with other TKIs at various concentrations decreased the cell viability and increased caspase 3/7 activity in MHCC97H cells ( FIGS. 31-39 ) and MHCC97L cells ( FIGS. 40-50 ) in a dose-dependent manner compared to those in vehicle-treated cells.
- EMT Epidermaal to Mesenchymal Transition
- HCC cells were seeded in the top chamber in 6 well transwell plates (Sigma-Aldrich, St. Louis, Mo.) at a density of 100,000 cells/500 ⁇ L/well in standard culture media containing 100 ⁇ StemXVivo® EMT Inducing Media Supplement (R&D systems, Minneapolis, Minn.) and was incubated overnight at 37° C. in humidified CO 2 incubator. Next day, EMT inducing media with or without the test articles was added and incubation was continued for 10 days with media changes every 3 days. On the 10th day, the number of cells migrated to the lower chamber was determined using Bio-Rad (Hercules, Calif.) automatic cell counter. Values obtained were expressed as a percentage of invasion and the cell counts of control cells were considered 100%.
- EMT Epithelial to Mesenchymal Transition
- mice were performed in accordance with the guidelines approved by the Institutional Animal Care and use committee of Washington Biotechnology Inc (Baltimore, Md.) where the studies were conducted.
- FIG. 66 Test agents were dissolved in chremophor/ethanol (1:1) to make a 5 ⁇ stock solution and diluted in water when used.
- Milciclib (30 mg/Kg), sorafenib (20 mg/Kg), milciclib+sorafenib or the corresponding vehicle was given orally to individual mice once daily from day 12 until day 47. After completion of the treatment at day 48, animals were euthanized and blood, liver tissues and tumor were collected for gene expression and mechanistic assays. Liver tumors developed 100% of animals challenged with orthotopic MHCC97H injection.
- Example 8 Milciclib Acts Via Specifically Downregulating MIR221/222
- miRNA from athymic nude mice following treatment with vehicle, milciclib, sorafenib, or milciclib+sorafenib was isolated from Total RNA using the TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific, Rockford, Ill.) according to the manufacturer's instructions. miRNA-221 and miR-222 quantifications were performed in duplicates using TaqMan Advanced miRNA Assay (Thermo Fisher Scientific, Rockford, Ill.) with a sample dilution of 1:10. The PCR mixture was incubated at 95° C. for 20 seconds, followed by 40 cycles of 95° C. for 3 seconds and 60° C. for 30 seconds. Results were normalized to hsa-miR-192-5p as reference miRNA and the relative gene expression calculated as 2- ⁇ CT was expressed as fold increase over control samples.
- the tumor tissues from a thymic nude mice were weighed and homogenized with RIPA lysis buffer (Sigma-Aldrich, St. Louis, Mo.) and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo.). Tumor lysates were cleared by centrifugation and the protein concentration was determined using Bradford reagent (Sigma-Aldrich, St. Louis, Mo.). Equal amounts of protein (30 ⁇ g) were resolved on precast polyacrylamide gels (Thermo Fisher Scientific, Rockford, Ill.) and transferred to nitrocellulose membrane, 0.2 ⁇ m pore size (Thermo Fisher Scientific, Rockford, Ill.).
- the blots were blocked with 5% (w/v) nonfat dry milk for 2 h at room temperature and then probed with primary antibody overnight at 4° C.
- the primary antibodies were directed against the following proteins: human PTEN, human AKT and phospho-AKT (Ser473), human c-Myc, human CyclinD1 and human (3-actin (Cell Signaling Technology, Beverly, Mass.). After three washes, incubation was followed by the reaction with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature.
- the immunoreactive bands were visualized using Image Studio 4.0-Western Analysis Ribbon (Li-Cor, Lincoln, Nebr.).
- Real-time quantitative PCR was employed using the LightCycler 480 Instrument II (Roche Diagnostics Corporation, Indianapolis, Ind.) using TaqMan Fast Advanced Master Mix and TaqMan Gene Expression probes for human p27, cyclin E2, cyclin A2, CdC6, MKI67, cyclin D1, p21, p57, c-Myc and p53 (Thermo Fisher Scientific).
- the expression of target genes was normalized to the housekeeping gene GAPDH in each sample. All samples were run in duplicate and the relative gene expression calculated as 2- ⁇ CT was expressed as fold increase over control samples.
- milciclib appears to be distinct from the mechanism of action of sorafenib as it upregulated the expression of tumor suppressors such as p27, p21, p53 and p57 ( FIGS. 72A , B, C, D).
- Mechanistic studies revealed a reduction in pAKT, c-Myc and cyclin D1 expression and upregulation of PTEN in liver samples derived from milciclib and milciclib and sorafenib administered animals as compared to vehicle treated group ( FIG. 75 ).
- MHCC97H cells were seeded at a density of 500,000 cells/2 mL/well on a 6 well culture plate and incubated overnight at 37° C. in a humidified CO 2 incubator. Cells were then treated with 1.3 ⁇ M milciclib or vehicle in DMEM/F12+2% FBS for 72 hours. Subsequently, cells were lysed in RIPA buffer, the supernatant was collected and used to perform ELISA assay as per the manufacturer's instructions. In orthotopic HCC mouse model, levels of serum marker alpha-fetoprotein (AFP) were determined on day 0, 6, 12, 18, 24, 30, 36, 42 and 48 using High Range AFP kit as per manufacturer's instructions.
- AFP serum marker alpha-fetoprotein
- Hepatocellular carcinoma is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis.
- a broad range of mechanisms including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response. Consequently, HCC is typically associated with overexpression of receptor tyrosine kinases (RTK) and excessive oxidative stress (ROS).
- RTK receptor tyrosine kinases
- ROS excessive oxidative stress
- HCC is also associated with overexpression of miR-221, miR-222 and CDKs, resulting in dysregulation of cell cycle, which leads to excessive proliferation of hepatocytes.
- Treatment with milciclib is known to inhibit miR-221/miR-222 and a number of CDKs and it can effectively reduce proliferation of hepatocytes. Therefore, collectively combination of milciclib with an inhibitor of RTK may produce synergistic effect in reducing expression of c-myc and in total tumor growth and progression.
- an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential.
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 16/182,036, filed Nov. 6, 2018, now allowed, which claims the benefit of, and priority to, U.S. Provisional Application No. 62/582,288, filed Nov. 6, 2017, each of which are incorporated by reference herein in their entireties for all purposes.
- This application relates generally to the treatment of cancers, and more particularly relates to the treatment of cancers with a combination of a cyclin-dependent kinase (CDK) inhibitor and at least one additional anticancer drug. The invention finds utility in the fields of medicine and pharmacotherapy.
- Milciclib, which may be referred herein to as
Compound 1, or N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide, has the following structure: - Milciclib is a small molecule inhibitor of multiple CDKs, including CDK1, CDK2, CDK4, CDK5, CDK7, and CDK9, and TRKs (TPKA and TRKC), has shown efficacy in several preclinical tumor models (Albanese C et al. (2010) Mol Cancer Ther 9:2243-2254.). In a phase I study, oral treatment with milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in thymic carcinoma, pancreatic carcinoma and colon cancer (Weiss G J et al. (2013) Invest New Drugs 31:136-144.) The major toxicity profile consisted of tremors and gastrointestinal toxicity which was reversible upon treatment suspension. Results from this study recommended a RP2D of 150 mg/day.
- Particularly, hepatocellular carcinoma (HCC) is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis. A broad range of mechanisms, including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response. Thus, an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential. Milciclib, exhibiting broad-spectrum inhibitory activities against CDKs, effectively retards proliferation of cancer cells. Therefore, it is reasonable to propose that anticancer activity of milciclib may be potentiated by an inhibitor of tyrosine kinase to produce synergistic anti-tumorigenic activity.
- There is a need for novel therapies by using milciclib in combination with a second anticancer drug or agent for the treatment of cancer. The present application addresses such a need.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a CDK inhibitor, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the CDK inhibitor is milciclib or a pharmaceutically acceptable salt thereof, and the other anticancer drug is sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is sorafenib or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma, hepatocellular carcinoma, or thyroid carcinoma.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is lenvatinib or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of lenvatinib is 8, 10, 12, 14, 18, 20, 22, 24, 26, 28, 30, 32, or 34 mg once daily.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma or thyroid carcinoma.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is regorafenib or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of regorafenib is 80, 100, or 120 mg once daily for three weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is colorectal cancer or gastrointestinal stromal tumors.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is sunitinib or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of sunitinib is 12.5, 25, 37.5, 50, 62.5, 75, 87.5, or 100 mg once daily continuously or for 4 weeks followed by two weeks of no administration, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is renal cell carcinoma or gastrointestinal stromal tumors.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is nivolumab.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is non-small cell lung cancer or renal cell carcinoma.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is gemcitabine or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of gemcitabine is 1000 mg/m2 over 30 minutes once weekly for seven weeks, followed by one week of no administration, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is breast cancer.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the other anticancer drug is palbociclib or a pharmaceutically acceptable salt thereof.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of palbociclib is 75, 100, or 125 mg once daily for 3 weeks followed by one week of no administration, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the cancer is breast cancer.
- In one aspect, this application pertains to a method of treating or preventing cancer in a patient in need thereof, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered to the patient simultaneously.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in a controlled release form.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are each administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein one or both of the pharmaceutical formulations is in a controlled release form.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and the other anticancer drug are administered to the patient sequentially.
- In one aspect, this application pertains to any of the methods described herein, wherein administration of milciclib begins before administration of the other anticancer to the patient.
- In one aspect, this application pertains to any of the methods described herein, wherein administration of milciclib begins after administration of the other anticancer to the patient.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is formulated for oral administration.
- In one aspect, this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in the form of a tablet, pill, or capsule.
- In one aspect, this application pertains to a method of treating or preventing renal cell carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- In one aspect, this application pertains to a method of treating or preventing hepatocellular carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- In one aspect, this application pertains to a method of treating or preventing thyroid carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof.
- In one aspect, this application pertains to any of the methods described herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- In one aspect, this application pertains to any of the methods described herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered to the patient simultaneously.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein the pharmaceutical formulation is in a controlled release form.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein one or both of the pharmaceutical formulations is in a controlled release form.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered to the patient sequentially.
- In one aspect, this application pertains to any of the methods described herein, wherein administration of milciclib begins before administration of sorafenib to the patient.
- In one aspect, this application pertains to any of the methods described herein, wherein administration of milciclib begins after administration of sorafenib to the patient.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are each administered in separate pharmaceutical formulations that each further include a pharmaceutically acceptable excipient.
- In one aspect, this application pertains to any of the methods described herein, wherein one or both pharmaceutical formulations are formulated for oral administration.
- In one aspect, this application pertains to any of the methods described herein, wherein each pharmaceutical formulation is independently in the form of a tablet, pill, or capsule.
- In one aspect, this application pertains to any of the methods described herein, wherein milciclib and sorafenib are administered in temporal proximity.
- In one aspect, this application pertains to any of the methods described herein, wherein the CDK inhibitor and the other anticancer drug are administered in temporal proximity.
- In one aspect, this application pertains to a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug.
- In one aspect, this application pertains to a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- In one aspect, this application pertains to the use of a pharmaceutical composition comprising milciclib or a pharmaceutically acceptable salt, isomer, or tautomer thereof, and another anticancer drug in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- In one aspect, this application pertains to milciclib for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with another anticancer drug.
- In one aspect, this application pertains to sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with milciclib.
- In one aspect, this application pertains to the use of milciclib in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with another anticancer drug.
- In one aspect, this application pertains to use of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma, by co-administration with milciclib.
- In one aspect, this application pertains to a product comprising milciclib, or a pharmaceutically acceptable salt thereof, and sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof, as a combined preparation for simultaneous, separate, or sequential use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.
- In one aspect, this application pertains to kit comprising:
- (a) a pharmaceutical composition comprising milciclib, or a pharmaceutically acceptable salt thereof;
- (b) a pharmaceutical composition comprising sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof; and
- (c) instructions for the use thereof in the treatment and/or prevention of cancer.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 is a graph showing the IC50 value of milciclib in MHCC97H cells. -
FIG. 2 is a graph showing the IC50 value of milciclib in MHCC97L cells. -
FIG. 3 is a graph showing the IC50 value of milciclib in HepG2.2.15 cells. -
FIG. 4 is a series of graphs depicting the IC50 of sorafenib, regorafenib, sunitinib, lenvatinib, and palbociclib in a MHCC97H cell proliferation assay. -
FIG. 5 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in MHCC97H cells. -
FIG. 6 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in MHCC97H cells. -
FIG. 7 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in MHCC97H cells. -
FIG. 8 is a set of two graphs showing the IC50 value of palbociclib and the combination of palbociclib and milciclib in MHCC97H cells. -
FIG. 9 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in MHCC97H cells. -
FIG. 10 is a graph showing the IC50 value of sunitinib in MHCC97L cells. -
FIG. 11 is a graph showing the IC50 value of sorafenib in MHCC97L cells. -
FIG. 12 is a graph showing the IC50 value of regorafenib in MHCC97L cells. -
FIG. 13 is a graph showing the IC50 value of lenvatinib in MHCC97L cells. -
FIG. 14 is a graph showing the IC50 value of palbociclib in MHCC97L cells. -
FIG. 15 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in MHCC97L cells. -
FIG. 16 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in MHCC97L cells. -
FIG. 17 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in MHCC97L cells. -
FIG. 18 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in MHCC97L cells. -
FIG. 19 is a set of two graphs showing the IC50 value of palbociclib and the combination of palbociclib and milciclib in MHCC97L cells. -
FIG. 20 is a graph showing the IC50 value of sunitinib in HepG2.2.15 cells. -
FIG. 21 is a graph showing the IC50 value of sorafenib in HepG2.2.15 cells. -
FIG. 22 is a graph showing the IC50 value of regorafenib in HepG2.2.15 cells. -
FIG. 23 is a graph showing the IC50 value of lenvatinib in HepG2.2.15 cells. -
FIG. 24 is a graph showing the IC50 value of palbociclib in HepG2.2.15 cells. -
FIG. 25 is a set of two graphs showing the IC50 value of sorafenib and the combination of sorafenib and milciclib in HepG2.2.15 cells. -
FIG. 26 is a set of two graphs showing the IC50 value of lenvatinib and the combination of lenvatinib and milciclib in HepG2.2.15 cells. -
FIG. 27 is a set of two graphs showing the IC50 value of regorafenib and the combination of regorafenib and milciclib in HepG2.2.15 cells. -
FIG. 28 is a set of two graphs showing the IC50 value of sunitinib and the combination of sunitinib and milciclib in HepG2.2.15 cells. -
FIG. 29A is a heat map depicting synergism between milciclib and sorafenib in MHCC97H cells. Milciclib concentration is varied on the y-axis and sorafenib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition. -
FIG. 29B is a heat map depicting synergism between milciclib and lenvatinib in MHCC97H cells. Milciclib concentration is varied on the y-axis and lenvatinib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition. -
FIG. 29C is a heat map depicting synergism between milciclib and regorafenib in MHCC97H cells. Milciclib concentration is varied on the y-axis and regorafenib concentration is depicted along the x-axis. Red depicts 100% inhibition while green depicts 0% inhibition. -
FIG. 30 is a graph showing changes in expression of alphafetoprotein (AFP) in MHCC97H cells treated with vehicle of milciclib. -
FIG. 31 is a series of graphs from the data collected in the Promega Triplex Assay of milciclib in MHCC97H cells. -
FIG. 32 is a series of graphs from the data collected in the Promega Triplex Assay of sorafenib in MHCC97H cells. -
FIG. 33 is a series of graphs from the data collected in the Promega Triplex Assay of regorafenib in MHCC97H cells. -
FIG. 34 is a series of graphs from the data collected in the Promega Triplex Assay of sunitinib in MHCC97H cells. -
FIG. 35 is a series of graphs from the data collected in the Promega Triplex Assay of lenvatinib in MHCC97H cells. -
FIG. 36 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sorafenib in MHCC97H cells. -
FIG. 37 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and regorafenib in MHCC97H cells. -
FIG. 38 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and lenvatinib in MHCC97H cells. -
FIG. 39 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sunitinib in MHCC97H cells. -
FIG. 40 is a series of graphs from the data collected in the Promega Triplex Assay of milciclib in MHCC97L cells. -
FIG. 41 is a series of graphs from the data collected in the Promega Triplex Assay of regorafenib in MHCC97L cells. -
FIG. 42 is a series of graphs from the data collected in the Promega Triplex Assay of sunitinib in MHCC97L cells. -
FIG. 43 is a series of graphs from the data collected in the Promega Triplex Assay of sorafenib in MHCC97L cells. -
FIG. 44 is a series of graphs from the data collected in the Promega Triplex Assay of lenvatinib in MHCC97L cells. -
FIG. 45 is a series of graphs from the data collected in the Promega Triplex Assay of palbociclib in MHCC97L cells. -
FIG. 46 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sorafenib in MHCC97L cells. -
FIG. 47 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and regorafenib in MHCC97L cells. -
FIG. 48 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and sunitinib in MHCC97L cells. -
FIG. 49 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and lenvatinib in MHCC97L cells. -
FIG. 50 is a series of graphs from the data collected in the Promega Triplex Assay of the combination of milciclib and palbociclib in MHCC97L cells. -
FIG. 51 is a series of photographs depicting the results of a wound-healing assay with milciclib in MHCC97H cells. -
FIG. 52 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in MHCC97H cells. -
FIG. 53 is a series of photographs depicting the results of a wound-healing assay with sunitinib and the combination of sunitinib and milciclib in MHCC97H cells. -
FIG. 54 is a series of photographs depicting the results of a wound-healing assay with lenvatinib and the combination of lenvatinib and milciclib in MHCC97H cells. -
FIG. 55 shows is a series of photographs depicting the results of a wound-healing assay with regorafenib and the combination of regorafenib and milciclib in MHCC97H cells. -
FIG. 56 is a series of photographs depicting the results of a wound-healing assay with milciclib in MHCC97L cells. -
FIG. 57 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in MHCC97L cells. -
FIG. 58 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of regorafenib and milciclib in MHCC97L cells. -
FIG. 59 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sunitinib and milciclib in MHCC97L cells. -
FIG. 60 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of lenvatinib and milciclib in MHCC97L cells. -
FIG. 61 is a series of photographs depicting the results of a wound-healing assay with milciclib in HepG2.2.15 cells. -
FIG. 62 is a series of photographs depicting the results of a wound-healing assay with sorafenib and the combination of sorafenib and milciclib in HepG2.2.15 cells. -
FIG. 63 is a series of photographs depicting the results of a wound-healing assay with regorafenib and the combination of regorafenib and milciclib in HepG2.2.15 cells. -
FIG. 64 is series of bar graphs displaying the results of an EMT assay with milciclib (A), regorafenib (B), sorafenib (C), sunitinib (D), and lenvatinib (E) in MHCC97L cells. -
FIG. 65 is series of bar graphs displaying the results of an EMT assay with milciclib (A), regorafenib (B), sorafenib (C), sunitinib (D), and lenvatinib (E) in MHCC97H cells. -
FIG. 66 is a schematic depicting the experimental design of in vivo studies wherein athymic mice with livers injected with MHCC97H cells were treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIG. 67 is a graph showing weight of mice livers following treatment via oral administration with sorafenib, milciclib, sorafenib+milciclib. -
FIG. 68 is a graph showing weight of mice liver tumors following treatment via oral administration with sorafenib, milciclib, sorafenib+milciclib. -
FIG. 69 is a series of photographs depicting changes in MHCC97H orthotopic HCC mouse liver tumor burden following treatment with vehicle, milciclib, sorafenib, or milciclib+sorafenib. -
FIG. 70 is a graph depicting changes in AFP serum levels in athymic mice with livers injected with MHCC97H cells were treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIGS. 71A and 71B are a series of graphs depicting relative expression of miR-221 (71A) and miR-222 (71B) miRNAs in athymic mice with livers injected with MHCC97H cells treated with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIG. 72 is a series of graphs depicting relative expression of p27kip1(A), p21 (B), p57 (C), and p53 (D) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIGS. 73A and 73B are a series of graphs depicting relative expression of Cyclin D1 (73A) and Cyclin E2 (73B) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIGS. 74A, 74B, and 74C are a series of graphs depicting relative expression of MKI67 (74A), c-Myc (74B) and Cdc6 (74C) in athymic mice with livers injected with MHCC97H cells following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib. -
FIG. 75 is a series of western blots depicting changes in expression of pAKTSer473, AKT, Cyclin D1, c-Myc, and PTEN in cells cultured from orthotopic HCC model mice following treatment with vehicle, sorafenib, milciclib, or milciclib+sorafenib. Actin is used as a loading control. -
FIG. 76 is a schematic depicting milciclib mechanism of action in hepatocellular carcinoma. - It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, “a CDK inhibitor” refers not only to a single inhibitor but also to a combination of two or more different inhibitors, “a dosage form” refers to a combination of dosage forms as well as to a single dosage form, and the like.
- Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which the invention pertains. Specific terminology of particular importance to the description of the present invention is defined below.
- As used herein, the term “patient” or “individual” or “subject” refers to any person or mammalian subject for whom or which therapy is desired, and generally refers to the recipient of the therapy to be practiced according to the invention.
- As used herein, the term “CDK inhibitor” refers to a compound that inhibits the enzyme in humans referred to as cyclin-dependent kinase. Examples include, without limitation, milciclib, palbociclib, dinaciclib, P276-00, roniciclib, ribociclib, P1446A-05, AT7519M, SNS-032, SCH 727965, AG-024322, hygrolidin, fascaplysin, abemaciclib, arcyriaflavin A, CINK4, AM-5992, CDK4 Inhibitor (CAS #546102-60-7), CDK4 Inhibitor III (CAS #265312-55-8), Cdk4/6 Inhibitor IV (CAS #359886-84-3), MM-D37K, NSC 625987, ON-123300, or any pharmaceutically acceptable salt thereof. (See Law, M. E. et al. “Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics” Mol. Pharmacol. 88:846-852 (2015), which is incorporated by reference herein in its entirety.). In one embodiment, the CDK inhibitor is milciclib.
- As used here, the term “anticancer drug” or “anticancer agent” includes kinase inhibitor drugs which refers to any member of the group of anticancer drugs that specifically targets protein kinases that are altered in cancer cells and account for some of their abnormal growth. In one embodiment, the anticancer drug is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or any pharmaceutically acceptable salt thereof. In one embodiment, the anticancer drug is sorafenib. In one embodiment, the anticancer drug is lenvatinib. In one embodiment, the anticancer drug is regorafenib. In one embodiment, the anticancer drug is sunitinib. In one embodiment, the anticancer drug is palbociclib.
- Other anticancer drugs, include, without limitation, an alkylating agent, an antibiotic, an anti-metabolite, a detoxifying agent, an interferon, a polyclonal or monoclonal antibody, an EGFR inhibitor, a HER2 inhibitor, a histone deacetylase inhibitor, a hormone; a mitotic inhibitor, an MTOR inhibitor, a multi-kinase inhibitor, a serine/threonine kinase inhibitor, a tyrosine kinase inhibitors, a VEGF/VEGFR inhibitor, a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), a cytidine analogue drug, or any chemotherapeutic, anti-neoplastic or anti-proliferative agent listed in www.cancer.org/docroot/cdg/cdg_0.asp. In one embodiment, the anticancer drug is nivolumab. In one embodiment, the anticancer drug is gemcitabine.
- When referring to an active agent, applicant intends the term “active agent” to encompass not only the specified molecular entity but also its pharmaceutically acceptable, pharmacologically active analogs, including, but not limited to, salts, esters, amides, prodrugs, conjugates, active metabolites, crystalline forms (including polymorphs), enantiomers, and other such derivatives, analogs, and related compounds.
- The terms “treating” and “treatment” include the following actions: (i) preventing a particular disease or disorder from occurring in a subject who may be predisposed to the disease or disorder but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease by reducing or eliminating symptoms and/or by causing regression of the disease.
- The term “unit dosage forms” as used herein refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients. It should be noted that, in some cases, two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of milciclib, such that the unit dosage in each tablet or capsule is approximately 50% of the therapeutically effective amount.
- By the terms “effective amount” and “therapeutically effective amount” of a compound is meant a nontoxic but sufficient amount of an active agent to provide the desired effect, i.e., treatment of cancer.
- As used herein, a “subject in need thereof” is a subject having cancer, or a subject having an increased risk of developing cancer relative to the population at large.
- The term “cancer” includes solid tumors, as well as, hematologic tumors and/or malignancies. A “cancer cell” or “cancerous cell” is a cell manifesting a cell proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells. Cancer cells can be identified by histological typing or grading of a tissue sample (e.g., a biopsy sample). Cancer cells can be identified through the use of appropriate molecular markers.
- Exemplary cancers include, but are not limited to, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodeimal tumors, visual pathway and hypothalamic glioma, breast cancer, triple negative breast cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid neoplasm, mycosis fungoides, Seziary Syndrome, endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor glioma, head and neck cancer, hepatocellular carcinoma, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, ocular cancer, islet cell tumors (endocrine pancreas), Kaposi's sarcoma, kidney cancer (renal cell carcinoma), renal cancer, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenstram macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, merkel cell carcinoma, mesothelioma malignant, mesothelioma, metastatic squamous neck cancer, mouth cancer, cancer of the tongue, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, chronic myelogenous leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low malignant potential tumor, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing family of sarcoma tumors, Kaposi Sarcoma, uterine cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, thyroid carcinoma, transitional cell cancer of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor, urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer, and Wilm's Tumor.
- The present application provides methods of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable carriers or excipients, in combination with a therapeutically effective amount of a second agent, i.e., an anticancer drug, with one or more pharmaceutically acceptable carriers or excipients, wherein the cancer is treated. In one embodiment, the anticancer drug is any compound disclosed herein other than milciclib.
- The cancer can be a hematologic tumor or malignancy, or a solid tumor (or tumors), or a refractory solid tumor.
- In one embodiment, the cancer is selected from the group consisting of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer (e.g., triple negative breast cancer), prostate cancer, pancreatic cancer, or thymoma (i.e., thymic carcinoma).
- This method of treating cancer includes a reduction in tumor size. Alternatively, or in addition, the cancer is metastatic cancer and this method of treatment includes inhibition of metastatic cancer cell invasion.
- The other anticancer drug or agent can be an alkylating agent; an antibiotic; an anti-metabolite; a detoxifying agent; an interferon; a polyclonal or monoclonal antibody; an EGFR inhibitor; a HER2 inhibitor; a histone deacetylase inhibitor; a hormone; a mitotic inhibitor; an MTOR inhibitor; a multi-kinase inhibitor; a serine/threonine kinase inhibitor; a tyrosine kinase inhibitors; a VEGF/VEGFR inhibitor; a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), a cytidine analogue drug or any chemotherapeutic, anti-neoplastic or anti-proliferative agent listed in www.cancer.org/docroot/cdg/cdg_0.asp.
- In one embodiment, the other anticancer agent is an anti-metabolite or a nucleoside analog. Exemplary anti-metabolites or nucleoside analogs include, but are not limited to, fluorouracil (Adrucil); capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purinethol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus); clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); cytarabine liposomal (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall); thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).
- In one embodiment, the other anticancer drug or agent is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- Milciclib or a pharmaceutically acceptable salt thereof, and/or the other anticancer drug, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the compound (i.e. including the active compound), and a pharmaceutically acceptable excipient or carrier. As used herein, “pharmaceutically acceptable excipient” or “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin.
- Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this application. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- In one aspect, milciclib, or a pharmaceutically acceptable salt thereof, and/or the other anticancer drug, is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, etc.) of milciclib, or a pharmaceutically acceptable salt thereof (as an active ingredient) and/or the other anticancer drug or agent, with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the application). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation.
- As used herein, “treating” describes the management and care of a subject for the purpose of combating a disease, condition, or disorder and includes decreasing or alleviating the symptoms or complications, or eliminating the disease, condition or disorder.
- As used herein, “preventing” describes stopping the onset of the symptoms or complications of the disease, condition or disorder.
- In one aspect, treating cancer results in a reduction in size of a tumor. A reduction in size of a tumor may also be referred to as “tumor regression.” Preferably, after treatment, tumor size is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Size of a tumor may be measured by any reproducible means of measurement. In a preferred aspect, size of a tumor may be measured as a diameter of the tumor.
- In another aspect, treating cancer results in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Tumor volume may be measured by any reproducible means of measurement.
- In another aspect, treating cancer results in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. Number of tumors may be measured by any reproducible means of measurement. In a preferred aspect, number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification. In a preferred aspect, the specified magnification is 2×, 3×, 4×, 5×, 10×, or 50×.
- In another aspect, treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. In a preferred aspect, the number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. In a preferred aspect, the specified magnification is 2×, 3×, 4×, 5×, 10×, or 50×.
- In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- In another aspect, treating cancer results in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not milciclib, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. In a preferred aspect, an increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. In another preferred aspect, an increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.
- In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. In a further aspect, treating cancer results a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not milciclib, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. Preferably, the mortality rate is decreased by more than 2%; more preferably, by more than 5%; more preferably, by more than 10%; and most preferably, by more than 25%. In a preferred aspect, a decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means. In another preferred aspect, a decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound. In another preferred aspect, a decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.
- In another aspect, treating cancer results in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Tumor growth rate may be measured by any reproducible means of measurement. In a preferred aspect, tumor growth rate is measured according to a change in tumor diameter per unit time.
- In another aspect, treating cancer results in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth may be measured by any reproducible means of measurement. In a preferred aspect, tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. In another preferred aspect, a decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.
- One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2005); Sambrook et al., Molecular Cloning, A Laboratory Manual (3d ed.), Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2000); Coligan et al., Current Protocols in Immunology, John Wiley & Sons, N.Y.; Enna et al., Current Protocols in Pharmacology, John Wiley & Sons, N.Y.; Fingl et al., The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 18th edition (1990). These texts can, of course, also be referred to in making or using an aspect of the application.
- The term “controlled release” or “controlled release form” refers to a drug-containing formulation or fraction thereof in which release of the drug is not immediate, i.e., with a “controlled release” formulation, administration does not result in immediate release of the drug into an absorption pool. The term is used interchangeably with “non-immediate release” as defined in Remington: The Science and Practice of Pharmacy, Nineteenth Ed. (Easton, Pa.: Mack Publishing Company, 1995). In general, the term “controlled release” as used herein includes sustained release and delayed release formulations.
- The term “sustained release” (synonymous with “extended release”) is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that preferably, although not necessarily, results in substantially constant blood levels of a drug over an extended time period. The term “delayed release” is also used in its conventional sense, to refer to a drug formulation which, following administration to a patient, provides a measurable time delay before drug is released from the formulation into the patient's body.
- By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. When the term “pharmaceutically acceptable” is used to refer to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration. “Pharmacologically active” (or simply “active”) as in a “pharmacologically active” derivative or analog, refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
- Administration of the active agents may be carried out using any appropriate mode of administration. Thus, administration can be, for example oral or parenteral, although oral administration is preferred.
- Depending on the intended mode of administration, the pharmaceutical formulation may be a solid, semi-solid or liquid, such as, for example, a tablet, a capsule, a caplet, a liquid, a suspension, an emulsion, a suppository, granules, pellets, beads, a powder, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. Suitable pharmaceutical formulations and dosage forms may be prepared using conventional methods known to those in the field of pharmaceutical formulation and described in the pertinent texts and literature, e.g., in Remington: The Science and Practice of Pharmacy (Easton, Pa.: Mack Publishing Co., 1995). Oral administration and therefore oral dosage forms are generally preferred, and include tablets, capsules, caplets, solutions, suspensions and syrups, and may also comprise a plurality of granules, beads, powders, or pellets that may or may not be encapsulated. Preferred oral dosage forms are capsules and tablets.
- As noted above, it is especially advantageous to formulate compositions of the invention in unit dosage form for ease of administration and uniformity of dosage. The term “unit dosage forms” as used herein refers to physically discrete units suited as unitary dosages for the individuals to be treated. That is, the compositions are formulated into discrete dosage units each containing a predetermined, “unit dosage” quantity of an active agent calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of unit dosage forms of the invention are dependent on the unique characteristics of the active agent to be delivered. Dosages can further be determined by reference to the usual dose and manner of administration of the ingredients. It should be noted that, in some cases, two or more individual dosage units in combination provide a therapeutically effective amount of the active agent, e.g., two tablets or capsules taken together may provide a therapeutically effective dosage of each active agent, such that the unit dosage in each tablet or capsule is approximately 50% of the therapeutically effective amount.
- Tablets may be manufactured using standard tablet processing procedures and equipment. Direct compression and granulation techniques are preferred. In addition to the active agent, tablets will generally contain inactive, pharmaceutically acceptable carrier materials such as binders, lubricants, disintegrants, fillers, stabilizers, surfactants, coloring agents, and the like.
- Capsules are also preferred oral dosage forms, in which case the active agent-containing composition may be encapsulated in the form of a liquid or solid (the latter including particulates such as granules, beads, powders or pellets). Suitable capsules may be either hard or soft, and are generally made of gelatin, starch, or a cellulosic material, with gelatin capsules preferred. Two-piece hard gelatin capsules are preferably sealed, such as with gelatin bands or the like. See, for example, Remington: The Science and Practice of Pharmacy, cited earlier herein, which describes materials and methods for preparing encapsulated pharmaceuticals.
- Generally, as will be appreciated by those of ordinary skill in the art, sustained release dosage forms are formulated by dispersing the active agents within a matrix of a gradually hydrolyzable material such as a hydrophilic polymer, or by coating a solid, drug-containing dosage form with such a material. Hydrophilic polymers useful for providing a sustained release coating or matrix include, by way of example: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, acrylic acid alkyl esters, methacrylic acid alkyl esters, and the like, e.g. copolymers of acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate; and vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, and ethylene-vinyl acetate copolymer.
- Sustained release dosage forms herein may be composed of the acrylate and methacrylate copolymers available under the tradename “Eudragit” from Rohm Pharma (Germany). The Eudragit series E, L, S, RL, RS, and NE copolymers are available as solubilized in organic solvent, in an aqueous dispersion, or as a dry powder. Preferred acrylate polymers are copolymers of methacrylic acid and methyl methacrylate, such as the Eudragit L and Eudragit S series polymers. In one embodiment, any of the pharmaceutical formulations may be formulated for sustained release, i.e., in a sustained release dosage form.
- Preparations according to this invention for parenteral administration include sterile aqueous and non-aqueous solutions, suspensions, and emulsions. Injectable aqueous solutions contain the active agent in water-soluble form. Examples of non-aqueous solvents or vehicles include fatty oils, such as olive oil and corn oil, synthetic fatty acid esters, such as ethyl oleate or triglycerides, low molecular weight alcohols such as propylene glycol, synthetic hydrophilic polymers such as polyethylene glycol, liposomes, and the like. Parenteral formulations may also contain adjuvants such as solubilizers, preservatives, wetting agents, emulsifiers, dispersants, and stabilizers, and aqueous suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and dextran. Injectable formulations are rendered sterile by incorporation of a sterilizing agent, filtration through a bacteria-retaining filter, irradiation, or heat. They can also be manufactured using a sterile injectable medium. The active agent may also be in dried, e.g., lyophilized, form that may be rehydrated with a suitable vehicle immediately prior to administration via injection.
- Each of the active agents may in addition be administered through the skin using conventional transdermal drug delivery systems, wherein the active agent or agents are contained within a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the drug composition is contained in a layer, or “reservoir,” underlying an upper backing layer. The laminated structure may contain a single reservoir, or it may contain multiple reservoirs. In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery. Alternatively, the drug-containing reservoir and skin contact adhesive are present as separate and distinct layers, with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form. Transdermal drug delivery systems may in addition contain a skin permeation enhancer.
- In addition to the formulations described previously, the active agents may be formulated in a depot preparation for controlled release of the active agents, preferably sustained release over an extended time period. These sustained release dosage forms are generally administered by implantation (e.g., subcutaneously or intramuscularly or by intramuscular injection).
- A “daily dose” of a particular material refers the amount of the material administered in a day. A daily dose can be administered as a single dose or as multiple doses. When a daily dose is administered as multiple doses, the daily dose is the sum of the amount of material administered in all of the multiple doses that are administered over the course of one day. For example, a daily dose of 12 mg can be administered in a single 12 mg dose once per day, in 6 mg doses administered twice per day, in 4 mg doses administered three times per day, in 2 mg doses administered six times per day, etc. The multiple doses can be the same or different doses of the material, unless otherwise specified. When a daily dose is administered as multiple doses, the multiple doses can be administered by the same or different route of administration, unless otherwise specified. Thus, a daily dose of 12 mg can include, for example, a 10 mg intramuscular dose and a 2 mg oral dose administered over the course of one day.
- Administration of one compound “with” a second compound, as used herein, includes but is not limited to cases where the two compounds are administered simultaneously or substantially simultaneously. For example, administration of a first compound with a second compound can include administering the first compound in the morning and administering the second compound in the evening, as well as administering the first and second compounds in the same dosage form or in two different dosage forms that at the same or nearly the same time.
- In combining the active agents disclosed herein, i.e., milciclib with another anticancer drug or agent disclosed herein, milciclib will generally reduce the quantity of the second drug or agent needed to achieve a therapeutic effect when administered as a monotherapy, and, conversely, the other anticancer drug or agent will generally reduce the quantity of milciclib required.
- As the method of the application involves combination therapy, the active agents may be administered separately, at the same or at different times of day, or they be administered in a single pharmaceutical formulation.
- In some embodiments, “temporal proximity” means that administration of the other anticancer drug occurs within a time period before or after the administration of the CDK inhibitor (e.g., milciclib), such that the therapeutic effect of the other kinase inhibitor drug overlaps with the therapeutic effect of the CDK inhibitor (e.g., milciclib). In some embodiments, the therapeutic effect of the other kinase inhibitor drug completely overlaps with the therapeutic effect of the CDK inhibitor (e.g., milciclib). In some embodiments, “temporal proximity” means that administration of the other kinase inhibitor drug occurs within a time period before or after the administration of the CDK inhibitor (e.g., milciclib), such that there is a synergistic effect between the other kinase inhibitor drug and the CDK inhibitor.
- “Temporal proximity” may vary according to various factors, including but not limited to, the age, gender, weight, genetic background, medical condition, disease history, and treatment history of the subject to which the therapeutic agents are to be administered; the disease or condition to be treated or ameliorated; the therapeutic outcome to be achieved; the dosage, dosing frequency, and dosing duration of the therapeutic agents; the pharmacokinetics and pharmacodynamics of the therapeutic agents; and the route(s) through which the therapeutic agents are administered. In some embodiments, “temporal proximity” means within 15 minutes, within 30 minutes, within an hour, within two hours, within four hours, within six hours, within eight hours, within 12 hours, within 18 hours, within 24 hours, within 36 hours, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within a week, within 2 weeks, within 3 weeks, within 4 weeks, with 6 weeks, or within 8 weeks. In some embodiments, multiple administration of one therapeutic agent can occur in temporal proximity to a single administration of another therapeutic agent. In some embodiments, temporal proximity may change during a treatment cycle or within a dosing regimen.
- IC50 values by cell proliferation assay were determined for MHCC97H and MHCC97L (highly metastatic hepatocellular carcinoma cell line, derived from humans) and HepG2.2.15 cells (derived from the human hepatoblastoma cell line HepG2). The cells were treated with milciclib, sorafenib, regorafenib, sunitinib, and lenvatinib, individually or in combination. Each inhibitor exhibited a dose dependent decrease in cell proliferation with comparable half maximal inhibitory concentration (IC50) across the three cell lines: (
FIGS. 1 and 4 —MHCC97H cells;FIGS. 2 and 10-14 —MHCC97L cells; andFIGS. 3 and 20-24 , HepG2.2.15 cells.) - A synergistic effect on inhibition of cell proliferation was observed upon treating MHCC97H, MHCC97L, and HepG2.2.15 cells with increasing concentration of TKIs (tyrosine kinase inhibitors) in the presence of fixed concentration corresponding to milciclib IC50 value. In all cases, the IC50 value of each TKI was reduced by ˜50% (MHCC97H:
FIGS. 5-9 ; MHCC97L:FIGS. 15-19 ; HepG2.2.15:FIGS. 25-28 ). - Increasing concentration of inhibitors with a fixed concentration of milciclib was tested on MHCC97L and MHCC97H cells to determine the synergistic effect on inhibition of cell proliferation. For sorafenib, the individual IC50 was 12 μM but with the combination with milciclib the IC50 was 6.7 μM in MHCC97H (
FIG. 29A ). For lenvatinib, the individual IC50 was 0.28 μM but with the combination with milciclib the IC50 was 0.12 μM in MHCC97H (FIG. 29B ). For regorafenib, the individual IC50 was 4.7 μM but with the combination with milciclib the IC50 was 1.9 μM in MHCC97H (FIG. 29C ). - MHCC97H cells were shown to produce human Alphafetoprotein (AFP)
- Appreciably lower levels of AFP were detected in milciclib treated cells as compared to vehicle control (
FIG. 30 ). - Promega ApoTox-Glo™ Triplex assays were also performed. Milciclib in combination with other TKIs at various concentrations decreased the cell viability and increased
caspase 3/7 activity in MHCC97H cells (FIGS. 31-39 ) and MHCC97L cells (FIGS. 40-50 ) in a dose-dependent manner compared to those in vehicle-treated cells. - Wound healing experiments were also performed. Treatment of scratched monolayer of MHCC97H cells with TKIs (tyrosine kinase inhibitors) in combination with milciclib (1.3 μM) for 96 h, reduced cell migration as compared to corresponding vehicle control (
FIGS. 51-55 ). Treatment of scratched monolayer of MHCC97L cells with milciclib alone or in combination with other TKIs for 96 hours, reduced cell migration as compared to corresponding vehicle control (FIGS. 56-60 ). Treatment of scratched monolayer of HepG2.2.15 cells with milciclib alone or in combination with other TKIs for 96 hours, reduced cell migration as compared to corresponding vehicle control (FIGS. 61-63 ). - EMT (Epithelial to Mesenchymal Transition) assays were also performed. Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P<0.005) (
FIG. 64 ). The inclusion of milciclib or TKIs alone resulted in statistically significant inhibition (P<0.05) in cell migration in MHCC97H cells. Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P<0.005), demonstrative of the anti-invasive potential of milciclib (FIG. 65 ). - Mouse experiments (tumor induction) were performed. Oral administration of milciclib (30 mg/kg/day) either alone or in combination with sorafenib (20 mg/kg/day) produced synergistic effect in reducing tumor growth [milciclib −20% (p<0.002) or sorafenib −21% (p<0.001) vs combination −38% (p<0.0002) as compared to vehicle (
FIG. 67 ). Vehicle group had more liver weight but with combination the liver weight goes down (FIG. 68 ). Pictures were taken showing the difference in tumor burden with the treatment of milciclib, sorafenib, and the combination. Vehicle group has an enlarged tumor but with the combination, the tumor burden goes down (FIG. 69 ). A steady increase in serum AFP was observed in vehicle administered animals until the end of the study. Significantly lower serum AFP levels were recorded for animals treated with milciclib (30 mg/kg), sorafenib (20 mg/kg) alone or in combination (FIG. 70 ). - It was determined that milciclib acts via specifically downregulating miR221/222. Gene expression studies suggest that milciclib possibly exerts its action through downregulation of miR-221 and miR-222. Data suggest that oral treatment with milciclib exerts its activity via downregulation of miR-221 and miR-222 (
FIGS. 71A and 71B ). These data suggest that milciclib specifically acts via reducing expression of miR-221 and miR-222, which are known to be major culprits of hepatocarcinogenesis. - Mechanism of action studies with milciclib were also performed. The mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib as it upregulated the expression of tumor suppressors such as p27, p21, p53 and p57 (
FIGS. 72A , B, C, D). Oral administration of milciclib alone or in combination with sorafenib downregulated expression of cyclins such as cyclin E2 and cyclin D1 (FIGS. 73A and 73B ). Oral administration of milciclib alone or in combination with sorafenib downregulated expression of cell proliferation genes such as MKI67, cdc6, c-Myc (FIGS. 74A, 74B, 74C ). The mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib. - Mechanistic studies revealed a reduction in pAKT, c-Myc and cyclin D1 expression and upregulation of PTEN in liver samples derived from milciclib and milciclib and sorafenib administered animals as compared to vehicle treated group (
FIG. 75 ). Data from cell culture studies and from orthotopic HCC model in nude mice suggest that oral treatment with milciclib exerts its activity via a new mechanism. - Hepatocellular carcinoma (HCC) is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis. A broad range of mechanisms, including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response. Consequently, HCC is typically associated with overexpression of receptor tyrosine kinases (RTK) and excessive oxidative stress (ROS). Collectively, overexpression of RTK and ROS lead to increased expression of c-myc, resulting in high metastatic potentials of hepatocytes. Thus, metastatic potential of hepatocytes can be reduced with specific inhibitors of RTK. On the other hand, HCC is also associated with overexpression of miR-221, miR-222 and CDKs, resulting in dysregulation of cell cycle, which leads to excessive proliferation of hepatocytes. Treatment with milciclib is known to inhibit miR-221/miR-222 and a number of CDKs and it can effectively reduce proliferation of hepatocytes. Therefore, collectively combination of milciclib with an inhibitor of RTK may produce synergistic effect in reducing expression of c-myc and in total tumor growth and progression. Thus, an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential. (
FIG. 76 ) - A pharmaceutical composition of the application is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- A compound or pharmaceutical composition of the application can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, for treatment of cancers, a compound of the application may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches. The dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects. The state of the disease condition and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
- The term “therapeutically effective amount,” as used herein, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. In a preferred aspect, the disease or condition to be treated is cancer. In another aspect, the disease or condition to be treated is a cell proliferative disorder.
- The therapeutically effective amount of milciclib is 1-500 mg administered one or more times over a day for up to 30 or more days, followed by 1 or more days of non-administration of milciclib. This type of treatment schedule, i.e., administration of milciclib on consecutive days followed by non-administration of milciclib on consecutive days may be referred to as a treatment cycle. A treatment cycle may be repeated as many times as necessary to achieve the intended affect.
- In one embodiment, the therapeutically effective amount of milciclib is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, or 500 mg once or twice daily for one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen consecutive days, followed by non-administration for one, two, three, four, five, six, or seven consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- In one embodiment, the therapeutically effective amount of milciclib is 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg once or twice daily for one, two, three, four, five, six, seven, eight, nine, or ten consecutive days, followed by non-administration for one, two, three, four, five, six, or seven consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- In one embodiment, the therapeutically effective amount of milciclib is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 mg once or twice daily for one, two, three, four, five, six, or seven consecutive days, followed by non-administration for one, two, three, four, five, six, or seven consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- In one embodiment, the therapeutically effective amount of milciclib is 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, or 125 mg once daily for four consecutive days, followed by non-administration for three consecutive days, wherein the cycle is optionally repeated 1, 2, or 3 times.
- For any compound, the therapeutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
- Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.
- The pharmaceutical compositions containing active compounds of the present application may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- In one aspect, the active compounds are prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the application are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
- In therapeutic applications, the dosages of the pharmaceutical compositions used in accordance with the application vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer. Dosages can range from about 0.01 mg/kg per day to about 3000 mg/kg per day. In preferred aspects, dosages can range from about 1 mg/kg per day to about 1000 mg/kg per day. In an aspect, the dose will be in the range of about 0.1 mg/day to about 50 g/day; about 0.1 mg/day to about 25 g/day; about 0.1 mg/day to about 10 g/day; about 0.1 mg to about 3 g/day; or about 0.1 mg to about 1 g/day, in single, divided, or continuous doses (which dose may be adjusted for the patient's weight in kg, body surface area in m2, and age in years). An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped. As used herein, the term “dosage effective manner” refers to amount of an active compound to produce the desired biological effect in a subject or cell.
- The pharmaceutical compositions can include co-formulations of milciclib and any of the compounds described herein.
- The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
- The present application also relates to the following:
- A. A method of treating or preventing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib, or a pharmaceutically acceptable salt thereof.
- B. A method of treating or preventing non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug.
- C. A method of treating or preventing non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- D. Any of methods disclosed herein, wherein the other anticancer drug is sorafenib or a pharmaceutically acceptable salt thereof. In one embodiment, the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily. In one embodiment, the cancer is renal cell carcinoma, hepatocellular carcinoma, or thyroid carcinoma.
- E. Any of methods disclosed herein, wherein the other anticancer drug is lenvatinib or a pharmaceutically acceptable salt thereof. In one embodiment, the therapeutically effective amount of lenvatinib is 8, 10, 12, 14, 18, 20, 22, 24, 26, 28, 30, 32, or 34 mg once daily. In one embodiment, the cancer is renal cell carcinoma or thyroid carcinoma.
- F. Any of methods disclosed herein, wherein the other anticancer drug is regorafenib or a pharmaceutically acceptable salt thereof. In one embodiment, the therapeutically effective amount of regorafenib is 80, 100, or 120 mg once daily for three weeks, followed by one week of no administration, wherein the cycle is optionally repeated. In one embodiment, the cancer is colorectal cancer or gastrointestinal stromal tumors.
- G. Any of methods disclosed herein, wherein the other anticancer drug is sunitinib or a pharmaceutically acceptable salt thereof. In one embodiment, the therapeutically effective amount of sunitinib is 12.5, 25, 37.5, 50, 62.5, 75, 87.5, or 100 mg once daily continuously or for 4 weeks followed by two weeks of no administration, wherein the cycle is optionally repeated. In one embodiment, the cancer is renal cell carcinoma or gastrointestinal stromal tumors.
- H. Any of methods disclosed herein, wherein the other anticancer drug is nivolumab. In one embodiment, the cancer is non-small cell lung cancer or renal cell carcinoma.
- I. Any of methods disclosed herein, wherein the other anticancer drug is palbociclib or a pharmaceutically acceptable salt thereof. In one embodiment, the therapeutically effective amount of palbociclib is 75, 100, or 125 mg once daily for 3 weeks followed by one week of no administration, wherein the cycle is optionally repeated. In one embodiment, the cancer is breast cancer.
- J. Any of methods disclosed herein, wherein the other anticancer drug is gemcitabine. In one embodiment, the therapeutically effective amount of gemcitabine is 1000 mg/m2 over 30 minutes once weekly for seven weeks, followed by one week of no administration, wherein the cycle is optionally repeated. In one embodiment, the cancer is breast cancer.
- K. Any of methods disclosed herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated. For example, the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is repeated as multiple times, e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more times. For example, the therapeutically effective amount of milciclib is about 100 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated. For example, the therapeutically effective amount of milciclib is 100 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- L. Any of methods disclosed herein, wherein milciclib and the other anticancer drug are administered to the patient simultaneously.
- M. Milciclib and the other anticancer drug are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient. In one embodiment, wherein the pharmaceutical formulation is in a controlled release form.
- N. Milciclib and the other anticancer drug are each administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient. In one embodiment, one or both of the pharmaceutical formulations is in a controlled release form.
- O. Any of methods disclosed herein, wherein milciclib and the other anticancer drug are administered to the patient sequentially. In one embodiment, the administration of milciclib begins before administration of the other anticancer drug to the patient. In one embodiment, the administration of milciclib begins after administration of the other anticancer drug to the patient.
- P. Milciclib is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient. In one embodiment, the other anticancer drug is administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient. In one embodiment, any of the pharmaceutical formulations are formulated for oral administration. For example, in one embodiment, the pharmaceutical formulation is in the form of a tablet, pill, or capsule.
- Q. Any of methods disclosed herein, wherein the method of treating or preventing renal cell carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib.
- R. Any of methods disclosed herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- S. Any of methods disclosed herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- T. Any of methods disclosed herein, wherein the method of treating or preventing hepatocellular carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib.
- U. Any of methods disclosed herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- V. Any of methods disclosed herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- W. A method of treating or preventing thyroid carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of sorafenib.
- X. Any of methods disclosed herein, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.
- Y. Any of methods disclosed herein, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.
- Z. Any of methods disclosed herein, wherein milciclib and sorafenib are administered to the patient simultaneously.
- AA. Any of methods disclosed herein, wherein milciclib and sorafenib are administered in a single pharmaceutical formulation that further includes a pharmaceutically acceptable excipient.
- BB. Any of methods disclosed herein, wherein the pharmaceutical formulation is in a controlled release form.
- CC. Any of methods disclosed herein, wherein milciclib and sorafenib are administered in separate pharmaceutical formulations, wherein each formulation further includes a pharmaceutically acceptable excipient. In one embodiment, one or both of the pharmaceutical formulations is in a controlled release form.
- DD. Any of methods disclosed herein, wherein milciclib and sorafenib are administered to the patient sequentially.
- EE. Any of methods disclosed herein, wherein, the administration of milciclib begins before administration of sorafenib to the patient.
- FF. Any of methods disclosed herein, wherein the administration of milciclib begins after administration of sorafenib to the patient.
- GG. Any of methods disclosed herein, wherein milciclib and sorafenib are each administered in separate pharmaceutical formulations that each further include a pharmaceutically acceptable excipient. In one embodiment, one or both pharmaceutical formulations are formulated for oral administration. For example, in one embodiment, each pharmaceutical formulation is independently in the form of a tablet, pill, or capsule.
- HH. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of cancer in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- II. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug.
- JJ. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- KK. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of cancer in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- LL. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug.
- MM. Milciclib, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, for use in the manufacture of a medicament for the treatment or prevention of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma in a patient in need thereof, further comprising the use of another anticancer drug that is selected from the group consisting of sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib.
- All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not to the remainder of the text of this application, in particular the claims of this application.
- It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention. It will be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the scope of the invention, and further that other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains.
- See Shailubhai, K et al. “Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis.” J Exp Ther Oncol. 2004; 4: 267-279; and Choudhari et al. “Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, atiprimod” Molecular Cancer Therapeutics. 2007; 6: 112-121. References are incorporated herein in their entireties.
- MHCC97H and MHCC97L (highly metastatic hepatocellular carcinoma cell line, derived from humans)
- HepG2.2.15 cells are derived from the human hepatoblastoma cell line HepG2.
- Cells (MHCC97H, MHCC97L, and HepG2.2.15) were cultured for 24 hours in 2% FBS and then were trypsinized, resuspended in 2% FBS and seeded in a rat collagen coated 96-well plate at a density of 10,000 cells/100 μl/well, a day before the experiment and cultured at 37° C. in 5% CO2. The cells were treated the next day with milciclib, sorafenib, regorafenib, sunitinib, and lenvatinib, individually or in combination in DMEM/F12+2% FBS+for 72 hours prior to the addition of WST-1 reagent. About 100 μL media was added to control well. After cells had been cultured for 72 hours with different drug concentrations, cells were washed 3 times with sterile 1× Phosphate buffered saline (PBS). To determine cell proliferation by the colorimetric test, 10 μL of WST-1 reagent (Sigma Aldrich, St Louis, Mo.) was added in 100 μL cell culture media and incubated for 2 hours in 5% CO2 at 37° C. At the end of incubation period, the plate was placed on a plate shaker for 1 minute and was monitored using a spectrophotometer at an optical density of 450 nm with a reference wavelength of 600 nm using Tecan F200 and iControl software. IC50 values were determined using GraphPad Prism (GraphPad Software, La Jolla, Calif.). Each experiment was performed in duplicate and repeated 2 times.
- Each inhibitor exhibited a dose dependent decrease in cell proliferation with comparable half maximal inhibitory concentration (IC50) across the three cell lines:
FIGS. 1 and 4 —MHCC97H cells;FIGS. 2 and 10-14 —MHCC97L cells; andFIGS. 3 and 20-24 —HepG2.2.15 cells. - Lenvatinib exhibited the lowest IC50 value followed by milciclib, regorafenib, sorafenib and sunitinib.
-
CELL LINE PROTEIN KINASE MHCC97H MHCC97L HepG2.2.15 INHIBITORS IC50, μM IC50, μM IC50, μM MILCICLIB 1.3 1 1.16 SORAFENIB 12.01 8.8 6.48 REGORAFENIB 4.7 3.5 3.94 LENVATINIB 0.28 0.14 0.24 SUNITINIB 30.48 8.2 25.43 PABLOCICLIB 14.5 8.2 11.11 -
-
IC50 (μM) IC50 (μM) OF KINASE PROTEIN KINASE KINASE INHIBITORS + INHIBITORS INHIBITORS 1.3 μM MILCICLIB SORAFENIB 12.01 6.7 REGORAFENIB 4.7 1.9 LENVATINIB 0.28 0.12 SUNITINIB 30.4 17.2 PALBOCICLIB 14.5 6.7 - A synergistic effect on inhibition of cell proliferation was observed upon treating MHCC97H, MHCC97L, and HepG2.2.15 cells with increasing concentration of TKIs in the presence of fixed concentration corresponding to milciclib IC50 value. In all cases, the IC50 value of each TKI was reduced by ˜50% (MHCC97H:
FIGS. 5-9 ; MHCC97L:FIGS. 15-19 ; HepG2.2.15:FIGS. 25-28 ). - Increasing concentration of inhibitors with a fixed concentration of milciclib was tested on MHCC97L and MHCC97H cells to determine the synergistic effect on inhibition of cell proliferation.
- In the synergy studies the arrow represents the mid-point of combination of TKIs with milciclib. For sorafenib, the individual IC50 was 12 μM but with the combination with milciclib the IC50 was 6.7 μM in MHCC97H (
FIG. 29A ). - For lenvatinib, the individual IC50 was 0.28 μM but with the combination with milciclib the IC50 was 0.12 μM in MHCC97H (
FIG. 29B ). - For regorafenib, the individual IC50 was 4.7 μM but with the combination with milciclib the IC50 was 1.9 μM in MHCC97H (
FIG. 29C ). - MHCC97H cells were seeded at a density of 500,000 cells/2 mL/well on a 6 well culture plate and incubated overnight at 37° C. in a humidified CO2 incubator. Cells were then treated with 1.3 μM milciclib or vehicle in DMEM/F12+2% FBS for 72 hours. Subsequently, cells were lysed in RIPA buffer, the supernatant was collected and used to perform ELISA assay as per the manufacturer's instructions. In orthotopic HCC mouse model, levels of serum marker alpha-fetoprotein (AFP) were determined on
day - Freshly cultured MHCC97H cells were treated with 1.3 μM milciclib for 72 hours to determine the AFP levels. Appreciably lower levels of AFP were detected in milciclib treated cells as compared to vehicle control (
FIG. 30 ). - The HCC cells were seeded at a density of 10,000 cells/100 μL in each well of a rat collagen coated 96 well plate and allowed to grow overnight in 5% CO2 at 37° C. The cells were then treated with different concentrations of each agent alone or in combination with 1.3 milciclib in MHCC97H and 1.16 μM milciclib in MHCC97L cells for 48 hours. Promega ApoTox-Glo Triplex assay (Madison, Wis.) was used according to manufacturer's instructions to determine the number of viable cells, cell death because of apoptosis and cytotoxic effect on cells. After 48 hours the viability/cytotoxicity reagent, containing both the GF-AFC substrate and the bis-AAF-R110 substrate, was added to all wells and incubated for 30 minutes and was measured at an optical density of 400EX/505EM for viability and 485EX/520EM for cytotoxicity. For apoptosis, caspase-
glo 3/7 was added to all wells, mixed briefly at 500 rpm for 30 seconds, then incubated at room temperature for 30 minutes and luminescence was measured which is proportional to the amount of caspase activity present. See Ito H, Uchida T, Makita K. Ketamine causes mitochondrial dysfunction in human induced pluripotent stem cell-derived neurons. PLoS One. 2015; 10: e0128445) for experimental details. Reference is incorporated herein in its entirety. - Milciclib in combination with other TKIs at various concentrations decreased the cell viability and increased
caspase 3/7 activity in MHCC97H cells (FIGS. 31-39 ) and MHCC97L cells (FIGS. 40-50 ) in a dose-dependent manner compared to those in vehicle-treated cells. - Cells were seeded at a density of 500,000 cells/2 mL/well on to a collagen-coated 6-well culture plate and incubated overnight in a humidified CO2 incubator at 37° C. to form a uniform monolayer. The monolayer was then scratched in a straight line with a new 104, pipette tip across the center of the well. After scratching, cells were washed with sterile PBS once to remove detached cells. Subsequently, wells were replenished with fresh DMEM/F12 containing 2% FBS and the test article either alone or in combination with milciclib. Photos were taken of the scratched monolayer immediately T0 and after
various times SlideBook™ 5 software. The values were expressed as a percentage of migration. See Saxena N K, Sharma D, Ding X, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007; 67: 2497-2507. - Treatment of scratched monolayer of MHCC97H cells with TKIs (tyrosine kinase inhibitors) in combination with milciclib (1.3 μM) for 96 h, reduced cell migration as compared to corresponding vehicle control (
FIGS. 51-55 ). - Treatment of scratched monolayer of MHCC97L cells with milciclib alone or in combination with other TKIs for 96 hours, reduced cell migration as compared to corresponding vehicle control (
FIGS. 56-60 ). - Treatment of scratched monolayer of HepG2.2.15 cells with milciclib alone or in combination with other TKIs for 96 hours, reduced cell migration as compared to corresponding vehicle control (
FIGS. 61-63 ). - EMT (Epithelial to Mesenchymal Transition) induction employing kit from R&D systems (Cat #CCM017)
- For transwell invasion assay HCC cells were seeded in the top chamber in 6 well transwell plates (Sigma-Aldrich, St. Louis, Mo.) at a density of 100,000 cells/500 μL/well in standard culture media containing 100× StemXVivo® EMT Inducing Media Supplement (R&D systems, Minneapolis, Minn.) and was incubated overnight at 37° C. in humidified CO2 incubator. Next day, EMT inducing media with or without the test articles was added and incubation was continued for 10 days with media changes every 3 days. On the 10th day, the number of cells migrated to the lower chamber was determined using Bio-Rad (Hercules, Calif.) automatic cell counter. Values obtained were expressed as a percentage of invasion and the cell counts of control cells were considered 100%.
- The invasive potential of cancer cells is dependent on losing epithelial characteristics and acquiring a migratory mesenchymal property referred to as Epithelial to Mesenchymal Transition (EMT).
- The inclusion of milciclib or TKIs alone resulted in statistically significant inhibition (P<0.05) in cell migration in MHCC97L cells. Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P<0.005) (
FIG. 64 ). - The inclusion of milciclib or TKIs alone resulted in statistically significant inhibition (P<0.05) in cell migration in MHCC97H cells. Regorafenib, sorafenib, sunitinib and lenvatinib in combination with milciclib reduced the invasion potential to a greater extent as compared to individual treatment (P<0.005), demonstrative of the anti-invasive potential of milciclib (
FIG. 65 ). - Mouse experiments were performed in accordance with the guidelines approved by the Institutional Animal Care and use committee of Washington Biotechnology Inc (Baltimore, Md.) where the studies were conducted. (
FIG. 66 ) Test agents were dissolved in chremophor/ethanol (1:1) to make a 5× stock solution and diluted in water when used. MHCC97H human liver cells (5×106) in PBS were mixed with 20% Matrigel and then inoculated orthotopically into the right flank of female Balb/c nude mice. Seven days after cell inoculation, the mice were randomly allocated to either the treatment group (n=12) or the control group (n=12) based on the levels of AFP. The daily animal inspection was conducted for general appearance and tumor growth. Milciclib (30 mg/Kg), sorafenib (20 mg/Kg), milciclib+sorafenib or the corresponding vehicle was given orally to individual mice once daily fromday 12 until day 47. After completion of the treatment atday 48, animals were euthanized and blood, liver tissues and tumor were collected for gene expression and mechanistic assays. Liver tumors developed 100% of animals challenged with orthotopic MHCC97H injection. - Oral administration of milciclib (30 mg/kg/day) either alone or in combination with sorafenib (20 mg/kg/day) produced synergistic effect in reducing tumor growth [milciclib −20% (p<0.002) or sorafenib −21% (p<0.001) vs combination −38% (p<0.0002) as compared to vehicle (
FIG. 67 ). Vehicle group had more liver weight but with combination the liver weight goes down (FIG. 68 ). - Pictures showing the difference in tumor burden with the treatment of milciclib, sorafenib, and the combination are provided. Vehicle group has an enlarged tumor but with the combination, the tumor burden goes down (
FIG. 69 ). - A steady increase in serum AFP was observed in vehicle administered animals until the end of the study. Significantly lower serum AFP levels were recorded for animals treated with milciclib (30 mg/kg), sorafenib (20 mg/kg) alone or in combination (
FIG. 70 ). - miRNA Isolation and Expression Analysis
- miRNA from athymic nude mice following treatment with vehicle, milciclib, sorafenib, or milciclib+sorafenib was isolated from Total RNA using the TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific, Rockford, Ill.) according to the manufacturer's instructions. miRNA-221 and miR-222 quantifications were performed in duplicates using TaqMan Advanced miRNA Assay (Thermo Fisher Scientific, Rockford, Ill.) with a sample dilution of 1:10. The PCR mixture was incubated at 95° C. for 20 seconds, followed by 40 cycles of 95° C. for 3 seconds and 60° C. for 30 seconds. Results were normalized to hsa-miR-192-5p as reference miRNA and the relative gene expression calculated as 2-ΔCT was expressed as fold increase over control samples.
- Gene expression studies suggest that milciclib possibly exerts its action through downregulation of miR-221 and miR-222.
- Data suggest that oral treatment with milciclib exerts its activity via downregulation of miR-221 and miR-222 (
FIGS. 71A and 71B ). - Tumor tissues from mice treated with vehicle, sorafenib, milciclib, milciclib+sorafenib and normal liver tissues from naive untreated mice were collected and levels of miR-221 and miR-222 were determined. The levels of both of miR-221 and miR-222 were elevated in tumors from vehicle treated mice. Treatment with sorafenib alone modestly reduced the expression of these miRs but treatment with milciclib alone significantly reduced expression of both miR-221 and miR-222. These data suggest that milciclib specifically acts via reducing expression of miR-221 and miR-222, which are known to be major culprits of hepatocarcinogenesis (See Park J K, et al. “miR-221 silencing blocks hepatocellular carcinoma and promotes survival.” Cancer Res. 2011; 71:7608-76.) These data also imply that oral treatment with milciclib reduced tumor growth via a mechanism distinct from orally administered sorafenib.
- The tumor tissues from a thymic nude mice were weighed and homogenized with RIPA lysis buffer (Sigma-Aldrich, St. Louis, Mo.) and protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo.). Tumor lysates were cleared by centrifugation and the protein concentration was determined using Bradford reagent (Sigma-Aldrich, St. Louis, Mo.). Equal amounts of protein (30 μg) were resolved on precast polyacrylamide gels (Thermo Fisher Scientific, Rockford, Ill.) and transferred to nitrocellulose membrane, 0.2 μm pore size (Thermo Fisher Scientific, Rockford, Ill.). The blots were blocked with 5% (w/v) nonfat dry milk for 2 h at room temperature and then probed with primary antibody overnight at 4° C. The primary antibodies were directed against the following proteins: human PTEN, human AKT and phospho-AKT (Ser473), human c-Myc, human CyclinD1 and human (3-actin (Cell Signaling Technology, Beverly, Mass.). After three washes, incubation was followed by the reaction with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The immunoreactive bands were visualized using Image Studio 4.0-Western Analysis Ribbon (Li-Cor, Lincoln, Nebr.).
- Total RNA was extracted using the RNeasy Mini kit according to the manufacturer's instructions (Qiagen, Germantown, Md.). RNA was quantified using Nanodrop Lite (Thermo Scientific, Wilmington, Del.). Complementary DNA (cDNA) synthesis was performed by reverse transcription of total RNA using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Rockford, Ill.). Real-time quantitative PCR was employed using the LightCycler 480 Instrument II (Roche Diagnostics Corporation, Indianapolis, Ind.) using TaqMan Fast Advanced Master Mix and TaqMan Gene Expression probes for human p27, cyclin E2, cyclin A2, CdC6, MKI67, cyclin D1, p21, p57, c-Myc and p53 (Thermo Fisher Scientific). The expression of target genes was normalized to the housekeeping gene GAPDH in each sample. All samples were run in duplicate and the relative gene expression calculated as 2-ΔCT was expressed as fold increase over control samples.
- The mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib as it upregulated the expression of tumor suppressors such as p27, p21, p53 and p57 (
FIGS. 72A , B, C, D). - Oral administration of milciclib alone or in combination with sorafenib downregulated expression of cyclins such as cyclin E2 and cyclin D1 (
FIGS. 73A and 73B ). - Oral administration of milciclib alone or in combination with sorafenib downregulated expression of cell proliferation genes such as MKI67, cdc6, c-Myc (
FIGS. 74A, 74B, 74C ). - The mechanism of action of milciclib appears to be distinct from the mechanism of action of sorafenib.
- Mechanistic studies revealed a reduction in pAKT, c-Myc and cyclin D1 expression and upregulation of PTEN in liver samples derived from milciclib and milciclib and sorafenib administered animals as compared to vehicle treated group (
FIG. 75 ). - Data from cell culture studies and from orthotopic HCC model in nude mice suggest that oral treatment with milciclib exerts its activity via a new mechanism.
- MHCC97H cells were seeded at a density of 500,000 cells/2 mL/well on a 6 well culture plate and incubated overnight at 37° C. in a humidified CO2 incubator. Cells were then treated with 1.3 μM milciclib or vehicle in DMEM/F12+2% FBS for 72 hours. Subsequently, cells were lysed in RIPA buffer, the supernatant was collected and used to perform ELISA assay as per the manufacturer's instructions. In orthotopic HCC mouse model, levels of serum marker alpha-fetoprotein (AFP) were determined on
day - Hepatocellular carcinoma (HCC) is an extremely complex multi-factorial condition associated with many confounding factors affecting disease course and patient prognosis. A broad range of mechanisms, including telomere dysfunction, activation of oncogenic pathways, abrogation of DNA damage checkpoints, activation of pro-inflammatory and metastatic pathways, and induction of the oxidative stress response. Consequently, HCC is typically associated with overexpression of receptor tyrosine kinases (RTK) and excessive oxidative stress (ROS). Collectively, overexpression of RTK and ROS lead to increased expression of c-myc, resulting in high metastatic potentials of hepatocytes. Thus, metastatic potential of hepatocytes can be reduced with specific inhibitors of RTK. On the other hand, HCC is also associated with overexpression of miR-221, miR-222 and CDKs, resulting in dysregulation of cell cycle, which leads to excessive proliferation of hepatocytes. Treatment with milciclib is known to inhibit miR-221/miR-222 and a number of CDKs and it can effectively reduce proliferation of hepatocytes. Therefore, collectively combination of milciclib with an inhibitor of RTK may produce synergistic effect in reducing expression of c-myc and in total tumor growth and progression. Thus, an effective therapy for HCC needs to control proliferation of hepatocytes and also suppress their metastatic potential. (
FIG. 76 )
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/914,703 US20200390769A1 (en) | 2017-11-06 | 2020-06-29 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762582288P | 2017-11-06 | 2017-11-06 | |
US16/182,036 US10758541B2 (en) | 2017-11-06 | 2018-11-06 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
US16/914,703 US20200390769A1 (en) | 2017-11-06 | 2020-06-29 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/182,036 Continuation US10758541B2 (en) | 2017-11-06 | 2018-11-06 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200390769A1 true US20200390769A1 (en) | 2020-12-17 |
Family
ID=64362773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/182,036 Active US10758541B2 (en) | 2017-11-06 | 2018-11-06 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
US16/914,703 Abandoned US20200390769A1 (en) | 2017-11-06 | 2020-06-29 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/182,036 Active US10758541B2 (en) | 2017-11-06 | 2018-11-06 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer |
Country Status (5)
Country | Link |
---|---|
US (2) | US10758541B2 (en) |
EP (1) | EP3706869A1 (en) |
JP (2) | JP7111811B2 (en) |
CA (1) | CA3076023A1 (en) |
WO (1) | WO2019090332A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220105037A (en) * | 2021-01-19 | 2022-07-26 | 인천대학교 산학협력단 | A Composition for Enhancing Anti-Cancer Effect of Sorafenib |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4062938A4 (en) * | 2019-11-18 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
CN110693839B (en) * | 2019-11-19 | 2022-03-08 | 乐普药业股份有限公司 | Solid dispersion of varlitinib mesylate and preparation method and application thereof |
CN112218626B (en) * | 2019-12-31 | 2023-03-24 | 广州帝奇医药技术有限公司 | Sustained release composition and preparation method thereof |
JP2021167301A (en) * | 2020-04-08 | 2021-10-21 | ファイザー・インク | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
CN112546048B (en) * | 2021-01-06 | 2022-11-29 | 天津科技大学 | HKL-5-61 and Osimertinib pharmaceutical composition and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US8084027B2 (en) * | 2006-02-10 | 2011-12-27 | Nerviano Medical Sciences S.R.L. | Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
US8518930B2 (en) * | 2008-07-29 | 2013-08-27 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent |
CN105294683B (en) | 2014-07-26 | 2018-01-23 | 广东东阳光药业有限公司 | Compound of CDK type small molecular inhibitors and application thereof |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
-
2018
- 2018-11-06 EP EP18804901.9A patent/EP3706869A1/en active Pending
- 2018-11-06 CA CA3076023A patent/CA3076023A1/en active Pending
- 2018-11-06 US US16/182,036 patent/US10758541B2/en active Active
- 2018-11-06 JP JP2020524839A patent/JP7111811B2/en active Active
- 2018-11-06 WO PCT/US2018/059451 patent/WO2019090332A1/en unknown
-
2020
- 2020-06-29 US US16/914,703 patent/US20200390769A1/en not_active Abandoned
-
2022
- 2022-07-21 JP JP2022116328A patent/JP2022136148A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220105037A (en) * | 2021-01-19 | 2022-07-26 | 인천대학교 산학협력단 | A Composition for Enhancing Anti-Cancer Effect of Sorafenib |
KR102597832B1 (en) | 2021-01-19 | 2023-11-02 | 인천대학교 산학협력단 | A Composition for Enhancing Anti-Cancer Effect of Sorafenib |
Also Published As
Publication number | Publication date |
---|---|
JP7111811B2 (en) | 2022-08-02 |
JP2022136148A (en) | 2022-09-15 |
CA3076023A1 (en) | 2019-05-09 |
WO2019090332A1 (en) | 2019-05-09 |
JP2021509395A (en) | 2021-03-25 |
US10758541B2 (en) | 2020-09-01 |
US20190134044A1 (en) | 2019-05-09 |
EP3706869A1 (en) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10758541B2 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
US8518930B2 (en) | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent | |
Temkin et al. | A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies | |
TWI449525B (en) | A synergistic pharmaceutical combination for the treatment of cancer | |
ES2361566T3 (en) | USE OF PARP-1 INHIBITORS. | |
CN111053768B (en) | Pharmaceutical combination for the treatment of melanoma | |
KR20210126653A (en) | Pharmaceutical Combination Comprising TNO155 and Ribociclib | |
US11524009B2 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
AU2017354903A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
EP2832358A1 (en) | Pharmaceutical kit for use in the treatment of colon and colorectal cancer | |
JP7001599B2 (en) | Dactinomycin Compositions and Methods for the Treatment of Acute Myeloid Leukemia | |
CN114727996A (en) | Azacitidine in combination with vinpocetine, Girestinib, midostaurin or other compounds for the treatment of leukemia or myelodysplastic syndrome | |
WO2012059526A1 (en) | Treatment of mastocytosis with masitinib | |
TW201244716A (en) | Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor | |
CN110652514A (en) | Pharmaceutical use of third generation EGFR inhibitor | |
JPH11501911A (en) | Treatment of diseases caused by cytokine growth factors | |
Lorusso et al. | Intravenous versus oral vinorelbine plus capecitabine as second-line treatment in advanced breast cancer patients. A retrospective comparison of two consecutive phase II studies | |
WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
KR20220098175A (en) | Therapeutic Combination of Acalabrutinib and Capivacertib to Treat B-Cell Malignancy | |
CA3228535A1 (en) | Combination therapy for the treatment of pan-kras mutated cancers | |
US11911374B2 (en) | Methods and uses for treating cancer | |
CN116390735A (en) | Combination of Bcl-2 inhibitors and hypomethylation agents for the treatment of cancer, uses and pharmaceutical compositions | |
CN114984015A (en) | Pharmaceutical combination composition for the treatment of proliferative diseases | |
JP2023549272A (en) | Use of trans-[tetrachloridobis(1H-indazole)sodium(III) ruthenate] to treat cancer | |
TW201307330A (en) | A pharmaceutical combination for the treatment of breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TIZIANA LIFE SCIENCES PLC, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHAILUBHAI, KUNWAR;REEL/FRAME:053072/0665 Effective date: 20190116 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |